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Histone deacetylase 7 (HDAC7) belongs to the class II HDAC family and plays a pivotal role 
in the maintenance of endothelium integrity. There are 8 splicing variants in mouse HDAC7 
mRNAs. Within the 5’ terminal non-coding area of some variants, there exist some short 
open reading frames (sORFs). Whether these sORFs can be translated and whether the 
resulting peptides play roles in cellular physiology remain unclear. In this study, we 
demonstrated that one sORF encoding a 7-amino-acid (7-aa) peptide could be translated in 
vascular progenitor cells (VPCs). Importantly, this 7-aa peptide (7A) could transfer the 
phosphate group from the phosphorylated Ser393 site of MEKK1 to the Thr145 site of 14-3-
3γ protein. The phosphorylated 7A (7Ap) could then directly phosphorylate 14-3-3γ protein 
in a cell-free, in-gel buffer system. The adjacent histidine and proline residues are essential 
for the phosphate group reception and transfer.  In vitro functional analyses revealed that 7A 
and 7Ap increased VPC self-renewal and migration and enhanced vascular endothelial 
growth factor (VEGF)-induced VPC migration and differentiation toward the endothelial cell 
(EC) lineage, in which MEKK1 and 14-3-3γ served as the upstream kinase and the 
downstream effector, respectively. Knockdown of either MEKK1 or 14-3-3γ attenuated 
VEGF-induced VPC migration and differentiation. Exogenous 7Ap could rescue the effect of 
VEGF on the MEKK1 siRNA-transfected VPCs but not on the 14-3-3γ siRNA-transfected 
VPCs. In vivo studies revealed that 7A, especially 7Ap, induced capillary vessel formation in 
Matrigel plug assays, increased re-endothelialization and suppressed neointima formation in 
the femoral artery injury model, and promoted foot blood perfusion recovery in the hindlimb 
ischemia model by increasing Sca1+ cell niche formation. These results indicate that the 
sORFs within the non-coding area can be translated and that 7A may play an important role 
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1.1 Stem cells and Adventitia progenitor cells 
1.1.1 Stem cell 
For over 30 years, research on stem cells has been identified as a promising area for 
regenerative medicine. Stem cells are a class of undeveloped cells that have the notable 
potential to develop into many specialized cell types, and have the ability of proliferation, 
self-renewal and regenerating tissues (Totey, Totey, Pal, & Pal, 2009; Tuch, 2006). The 
widely recognized definition of a stem cell distinguished from other cell types requires two 
important characteristics: 
1. Self-renewal: they are undeveloped cells capable of renewing themselves through many 
cycles of cell division while maintaining the undifferentiated state. 
2. Potency: they have the capacity to be induced to differentiate to tissue- or organ-specific 
cells with special functions under certain environment conditions, which requires stem cells 
to be either totipotent or pluripotent. Totipotency is the ability of a single cell to divide and 
produce all of the differentiated cells in an organism. Pluripotency refers to a stem cell that 
has the potential to differentiate into any of the three germ layers. At the beginning of human 
development, a sperm fertilizes an egg and the resulting fertilized egg creates a single 
totipotent cell, a zygote. In the first hours after fertilization, this zygote divides into identical 
totipotent cells. Approximately four days after fertilization, these totipotent cells begin to 
specialize and becomes pluripotent cells (Asch, Simerly, Ord, Ord, & Schatten, 1995; 





Figure 1.1 Differentiation of stem cells 
 
Totipotent stem cells can differentiate into both embryonic and extraembryonic cell types. 
Such cells from an earlier stage of the embryo can construct a complete and viable organism. 
Pluripotent stem cells are the descendants of totipotent cells and can differentiate into nearly 
all cells derived from any of the three germ layers. Multipotent stem cells can differentiate 
into a number of cells, but only those of a closely related family of cells. 
 
1.1.1.1 Embryonic stem cell 
In mammals, parallel to former estimation, a rough classification classifies stem cells into 
embryonic stem cells (ESCs) and nonembryonic stem cell. ESCs derived from the inner cell 
mass of blastocyst stage embryos, are pluripotent stem cells with self-renewal ability and 
have an unlimited capacity to differentiate into all cell types. Many studies have successfully 
driven ESCs to differentiate into specific cell type lineages, such as endothelial cell (EC) and 
smooth muscle cells (SMCs) in various conditions. More established methods, including 
supplement ESC culture medium with VEGF for more than 21 days can induce EC-
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differentiation (Xiao et al., 2006); while treatment of ESCs with PDGF-BB when cultivated 
on collagen-IV coated flasks will lead to SMC-differentiation (Xiao, Zeng, Zhang, Hu, & Xu, 
2007). As SMCs and ECs are main cell types in the vascular wall, the ESC-derived smooth 
muscle cell (SMC) and endothelial cell (EC) will play crucial roles in treatment of 
cardiovascular diseases.  
 
1.1.1.2 Adult stem cells 
Expect embryonic development,  stem cells also function as a sort of internal repairing 
system in many tissues, dividing essentially to replenish other cells throughout the life span 
of the organism. These cells are identified as adult stem cells, which have been found in 
different tissues and organs around the whole body. They can renew themselves and 
differentiate into specific lineages of cells found within the tissues they are located in. In 
some organs, stem cells regularly divide to repair and replace worn out or damaged tissues, 
such as the gut and bone marrow. In other organs, however, stem cells only divide under 
special conditions. Normally, when a stem cell divides, the new cell can remain a stem cell or 
become a differentiated cell with more specialized function, such as a heart cell. However, 
unlike ESC, which are known to be derived from blastocysts, the origins of some adult stem 
cells in specific tissues remain uncertain, though several adults stem cells have been 
identified such as  hematopoietic stem cells and bone marrow stromal stem cells (Thomas, 
Lochte, Lu, & Ferrebee, 1957).  
The microenvironment of the body which harbours the adult stem cells is called the “stem 
cell niche”. A specific niche is thought to exist in many tissues and organs, such as: bone 
marrow, peripheral blood, heart, skin, brain and blood vessel wall (Birbrair & Frenette, 2016; 
Kopp, Hooper, Avecilla, & Rafii, 2009). Normally, adult stem cells are maintained in a 
quiescent state in the niche, but once they received stimulation signals from surrounding 
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injured tissues, the cells are activated to proliferate, migrate and differentiate to form new 
tissue (Scadden, 2006).  
The advantages of adult stem cells are easy harvest and individual which will not be rejected 
by the immune system once transplanted back to the donor.  In addition, they are possible to 
be stimulated in local tissue which would be more effective applying to therapy. 
 
Figure 1.2 Development of human embryonic and adult stem cells.  
 
Human ESCsare derived from the inner cells of a blastocyst which is the divided product of a 
zygote, a fusion of the egg and sperm. These ESCsare either self-renewing or pluripotent. 
Human adult stem cells reside in different adult tissues and they are also capable of self-
renewal and multipotent differentiation. Whether differentiated cells are lineage restricted to 
the original organs of their origin or have potential to differentiate into other cell types 







1.1.2 Adventitia progenitor cells 
1.1.2.1 Adventitia and its function 
The adventitia, outermost connective tissue of most blood vessel walls, has been regarded as 
a network of connective tissue, including fibroblasts, perivascular nerves, and microvessels 
implanted in a collagen-rich extracellular matrix (ECM) (Majesky, Dong, Hoglund, Daum, & 
Mahoney, 2012). The vascular adventitia acts as a biological processing centre for the 
retrieval, integration, storage, and release of key regulators for the vessel wall function 
(Stenmark, Davie, Frid, Gerasimovskaya, & Das, 2006; Stenmark et al., 2013). It plays an 
important role in the blood vessel growth and repair and mediates cross talk between different 
cell types residing in the vessel wall. 
 
Figure 1.3 Cellular components of the adventitia of vessel wall.  
 
The adventitia interacts with other layers of the vessel wall (top) and the surrounding tissues 
in which the vessel is located (bottom). Because of their specific loci, adventitial cells can 
participate in vessel formation, repair and disease processes. Lu, lumen; In, intima; Me, 
media; Ad, adventitia (Majesky, Dong, Hoglund, Mahoney, & Daum, 2011).  
 
1.1.2.2 Adventitial progenitor cell 
Adult blood vessels were believed to be quiescent, and not thought to contribute to new blood 
vessel formation until 1971. Based on observations of tumour tissue vascularisation, Judah 
Folkman and colleagues hypothesised that new vessels were formed via angiogenesis - a 
process in which new vessels grow from pre-existing vessels (Folkman, 1971). In the last 
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decade, the majority of experimental studies postulate that stem/progenitor cells reside in two 
main zones within the vessel wall i.e. the sub-endothelial zone (micro-vessel wall) and the 
adventitia (medium and large blood vessels) (Alessandri et al., 2001; E. L. Ergun, Caglar, 
Bozkurt, & Ergun, 2008; Pasquinelli et al., 2007; Peault et al., 2007). Though there is still 
some debate, it is widely believed that new vessel formation is in part dependent on 
stem/progenitor cells that reside within the vascular wall (Hu, Davison, et al., 2002; Hu, 
Mayr, et al., 2002).  
Adventitial vasa vasorum constitutes a complete vascular tree-like structure, including 
arterioles, capillaries, and veins (Langheinrich, Kampschulte, Buch, & Bohle, 2007). Recent 
studies suggest a more complex and dynamic picture of the adventitia which emphasizes 
critical roles played by interacting adventitial cell types in growth, inflammation, repair, and 
disease of the artery wall (Majesky et al., 2012). It is known that normal adventitia contains 
resident macrophages, mast cells, T cells, B cells, and dendritic cells (Galkina et al., 2006; 
Mayranpaa et al., 2009; Swedenborg, Mayranpaa, & Kovanen, 2011; Zhou et al., 2010). 
However, recently accumulating evidence shows that the adventitia contains resident vascular 
stem cells/progenitor cells (Campagnolo et al., 2010; Hoshino, Chiba, Nagai, Ishii, & Ochiai, 






Figure 1.4 Subsets of vessel wall stem cells and their differentiation capacities.  
 
Many studies have identified different populations of progenitor cells in the vascular 
adventitia using a variety of markers. These cells show a variety of differentiation 
capacities(S. Ergun et al., 2011).  
 
As shown in Figure 1.4, CD34+ cells are found in the vasculogenic zone, which potentially 
includes two subsets: CD34+VEGFR-2+Tie+CD31- cells that differentiate into ECs and 
CD34-CD3-CD44+CD90+CD105+CD73 cells that differentiate into vascular SMCs. 
Additionally, vessel wall resident mesenchymal stem cells have also been identified within 
the native adventitial niche and can similarly differentiate into SMCs. Furthermore, 
adventitial Sca-1+ cells that reside within the vasculogenic zone from embryonic 
development to adulthood have the capacity to differentiate into SMCs in vitro under specific 
culture conditions. Finally, CD45+CD133+CD34-cells have been found to give rise to 
macrophages and other inflammatory cells.  
Accumulating evidence indicates the existence of two types of circulating ECs. 5% of which 
are bone marrow–derived endothelial progenitor cells originated from hematopoietic stem 
cells(Lin, Weisdorf, Solovey, & Hebbel, 2000; Rafii, 2000), which are positive for CD34 and 
Flk-1 or vascular endothelial growth factor receptor 2 (VEGFR-2) (Crosby et al., 2000). The 
major proportion (>95%) of endothelial (progenitor) cells in blood originates from non–bone 
marrow tissues (Gunsilius et al., 2000; Lin et al., 2000). Hu et al reported that adventitia 
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progenitors could differentiate to SMC and EC in response to VEGF stimulation, which 
suggest that adventitial Sca-1+ cells also have the potential to differentiate into both ECs and 
SMCs. They found that only the adventitia of the vessel wall contained large numbers of 
these marker-positive cells, and it was rare to see positive cells in the intima and media of the 
artery and heart tissues. Furthermore, these positive cells were more abundant in the region of 
the aortic root than in other areas of the adventitia. So, adventitial cells from aortic roots were 
cultivated using stem cell culture medium to prevent cell differentiation. Zorzi et al reported 
that rat thoracic aorta contained adventitial macrophage-like cells which were capable to 
proliferate, differentiate into macrophages and dendritic cells, and stimulate angiogenesis. A 
subset of these cells acquired an EC phenotype when cultured in the presence of VEGF and 
formed capillary-like vascular structures in a matrigel angiogenesis assay in vitro (Zorzi, 
Aplin, Smith, & Nicosia, 2010).  
Under pathological conditions, the arterial adventitia undergoes remodelling in response to a 
variety of arterial injuries. The resident adventitial cells are often the first to be activated and 
reprogrammed in arterial wall remodelling, which may contain several pathological entities: 
the adventitial adaptive immune response predominates in chronic rejection; the adventitial 
sprouting of neovessels, leading to intraplaque haemorrhages, predominates in 
atherothrombosis; the adventitial fibrosis characterizes the response to mechanical stress the 
constrictive remodelling of arterial segments and initiating interstitial fibrosis in perivascular 
tissues (Michel et al., 2007).  
In summary, these findings suggest that the adventitia maintains multiple types of progenitor 
cells that appear to act in concert as part of a coordinated healing response to vascular injury. 




1.2 Endothelial cell 
The maintenance of blood fluidity is controlled by the inner lining of the circulatory 
system—the endothelium, a thin layer of cells, which lines the interior surface of blood 
vessels and lymphatic vessels (Risau, 1997). The cells that form the endothelium are called 
ECs, which can be divided into lymphatic ECs contacting with lymph, and vascular ECs 
contacting with blood. Due to their position at the interface between blood and tissues, 
vascular ECs control blood fluidity and continue tissue perfusion, at the same time, they 
direct inflammatory cells to areas in need of defence or repair (van Hinsbergh, 2012). 
(http://biology4isc.weebly.com/4-circulatory-system.html) 
Figure 1.5 Structure of a blood vessel wall.  
 
There are three layers of arteries and veins: Tunica intima (the thinnest layer), which has flat 
ECs lined by elastic membrane; Tunica media (the thickest layer in arteries), which formed 
by a thick coat of SMCs; Tunica adventitia: (the thickest layer in veins), which is made up of 
loosely arranged elastic and collagen fibres. 
 
 
1.2.1 Endothelial cell in angiogenesis 
ECs form cell-cell junctions that modulate cell signalling, functioning as selectively 
permeable barriers between blood and tissues. They also play an essential role in 
angiogenesis. In a healthy adult, quiescent ECs form a monolayer of phalanx cells, 
interconnected by junctional molecules such as claudins and vascular endothelial cadherin 
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(VE-cadherin or CD144). VE-cadherin makes adherens junction forming between ECs and 
regulates angiogenesis by controlling ECs adhesion, migration, proliferation, and survival via 
interactions with VEGF receptors. VEGF is involved in new vessel formation during 
embryogenesis and in proliferative diseases in adults by inducing differentiation in vascular 
structures and ECs proliferation. 
In angiogenesis, ECs proliferate, migrate, and coalesce to form primitive vascular network, in 
response to angiogenic stimuli，which needs recruitment of SMCs to become mature blood 
vessels. Then ECs resume their quiescent phalanx state, and signals such as platelet-derived 
growth factor B (PDGF-B), transforming growth factor-β (TGF-β), ephrin-B2 and NOTCH 
cause the cells to become covered by pericytes and protease inhibitors induce the junctions 
re-established to ensure optimal flow distribution, which makes a mature vessel stable and 
functional (Herbert & Stainier, 2011). For the de novo formation of embryonic blood vessels, 
ECs undergo specification to either arterial or venous fate immediately following original 
vascular network created, which includes the differentiation, migration and coalescence of 
mesoderm-derived endothelial progenitors (angioblasts). During embryogenesis, ECs plant 
into nascent organs to give inductive signals to promote organogenesis, even in the absence 
of blood flow. This indicates that ECs not only form passive conduits for delivering but also 
establish organ-specific vascular niches, which stimulate organogenesis by releasing 
paracrine-tropic 'angiocrine' factors (Peter Carmeliet & Jain, 2011; Rocha & Adams, 2009). 
 
1.2.2 Endothelial cell injury and repair 
EC injury, resulting in endothelial dysfunction or the loss of proper endothelial function, is 
often regarded as a hallmark in the development of cardiovascular diseases. ECs injury would 
cause a complex cascade of events, such as endothelial denudation, platelet activation, 
growth factor release and further neointima formation (Tesfamariam, 2008). The factors 
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cause ECs injury are various under different status. In vivo,  the major risk factor for ECs 
injury is  shear stress that activates the endothelium and induces cell migration, proliferation 
and apoptosis, resulting in an increase in endothelium permeability, leukocyte and monocyte 
adhesion (Hahn & Schwartz, 2009).  Post angioplasty, ECs are injured and activated by the 
implanted stent, which induces leukocytes adhesion by increasing expression of P-selectin, 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1(ICAM-1), 
tumor necrosis factor alpha (TNF-α) and other inflammatory cytokines. Besides, injured ECs 
are also associated with thrombosis through inhibition of thrombomodulin (Pober & Sessa, 
2007) and dysfunction in maintenance of vascular homeostasis through  reducing endothelial 
nitric oxide synthase (eNOS) activity but increasing reactive oxygen species, which further 
impairs ECs and continuously induces inflammatory signalling(Cai, 2005). 
Re-endothelialisation is a self-repair process after injury to maintain the protective role of 
endothelium in the vessel wall, which includes proliferation and migration of adjacent intact 
ECs, resident vascular stem cells/progenitor cells and recruited stem cells from the bone 
marrow. The vasculogenic zone is located between the adventitia and the media, where cells 
identified as CD34+CD31- are described as progenitors with the ability to differentiate into 
ECs, to participate in blood vessel formation and progression of atherosclerosis (Hu & Xu, 
2011). Blann et al has proved that resident vascular-derived ECs contribute to endothelium 
repairing much more effectively in response to damaging stimulation than bone marrow 
originating stem cells (Blann et al., 2005), which indicates that stimulating resident stem cell 
to participate into endothelium repairing have therapeutic potential in angiogenesis/ 
vasculogenesis.  
In atherosclerosis, adventitial inflammation and angiogenesis are widespread, resident stem 
or progenitor cells performing different structural and functional behaviours in response to 
injury and atherosclerotic plaques (Gutterman, 1999). In normal conditions, progenitor cells 
30 
 
are involved in maintaining homeostasis of the vasculature, while under pathological status, 
progenitor cells may also participate in neointimal lesion formation and atherosclerosis. It is 
believed that the media and adjacent undamaged cells, such as mature ECs and SMCs can 
migrate into the intima to replace dead ECs (Ross, Glomset, & Harker, 1977). Multiple 
research groups have demonstrated that in porcine coronary arteries and canine and rat 
carotid arteries, the increase in adventitial cell proliferation and migration in response to 
injury contributes greatly to neointimal lesion formation (Holifield et al., 1996; Mason et al., 
1999; Oparil et al., 1999; Scott et al., 1996; Shi et al., 1996). In addition, SMCs and ECs in 
atherosclerotic plaques are reported to be derived from local resident progenitor cells in the 
vessel wall rather than bone marrow-derived progenitor cells (Xu, 2004). A direct evidence 
for the ability of adventitial cell migration was provided by monitoring the movement of 
transplanted cells to the adventitia of the injured artery (Stenmark et al., 2013).  
Recently, it became more and more attractive that stimulation of vessel wall resident 
progenitor cell or recruitment of bone-marrow-derived cells could repair adult injured vessels 
and the expansion of pathological vessels, as the progenitor cells would become incorporated 
into the endothelium in a process known as postnatal vasculogenesis (Schaper, 2009). What 









1.3  Histone deacetylase  
The homeostasis of histone acetyltransferase (HAT) and histone deacetylase (HDAC) is 
known to play a central role in the regulation of gene expression, through the modulation of 
chromosome assembly/disassembly and affects transcription factors access to DNA (J. H. 
Lee, Hart, & Skalnik, 2004). Acetylation describes a reaction that introduces an acetyl group 
(resulting in an acetoxy group) into a compound, namely the substitution of an acetyl group 
for an active hydrogen atom. The reaction involving the replacement of the hydrogen atom of 
a hydroxyl group with an acetyl group (CH3 CO) yields a specific ester, the acetate. The 
opposite chemical reaction is called deacetylation – it is the removal of the acetyl group. 
Histone acetylation and deacetylation involve the addition or removal of an acetyl moiety 
from acetyl co-enzyme A to lysine residues in the N-terminal tail on the surface of the 
nucelosome core of histone proteins, which is essential in gene regulation (Wu, Suka, Carlson, 
& Grunstein, 2001; X. J. Yang & Seto, 2003). For acetylated and deacetylated histones are 
considered epigenetic tags within chromatin by relaxing (euchromatin) or tightening 
(heterochromatin) chromatin structure, subsequently increasing or decreasing gene 
transcription levels. Acetylation removes the positive charge on the histones, thereby 
decreasing the interaction of the N termini of histones with the negatively charged phosphate 
groups of DNA. As a consequence, the condensed chromatin is transformed into a more 
relaxed structure that is associated with greater levels of gene transcription. This relaxation 
can be reversed by HDAC activity (Verdone, Agricola, Caserta, & Di Mauro, 2006). 
HDACs are a family of enzymes that remove acetyl groups from the N-acetylated lysine 
residues on histones (Berndsen & Denu, 2008). Accumulating evidence indicates that 
HDACs are part of transcriptional co-repressor complexes and  play a fundamental role in 
transcriptional regulation, cell-cycle progression, cell proliferation, cell differentiation and 
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contribute to developmental events (Kato, Tamamizu-Kato, & Shibasaki, 2004; Sterner & 
Berger, 2000). 
 
Figure 1.6 HAT and HDAC  
 
HDACs repress transcription by deacetylation of the N-terminal tails of core-histions, which 
results in chromatin condensation. In contrast, HATs, such as p300 and PCAF antagonize the 
repressive activity of HDACs and acetylate the histone tails, nu relaxing chromatin and 
weakening the electrostatic interaction between positively charges histone tails and 
negatively charged DNA. 
 
 
1.3.1 Members and characteristics of HDACS family  
Mammalian genome encodes 18 HDACs, which  can be grouped into four classes based on 
the homology with yeast HDACs (Thiagalingam et al., 2003). All members share a highly 
conserved deacetylase domain but differ in structure, subcellular localization and expression 
pattern, which results in different cellular functions (Dario Ummarino, 2013). Class I HDACs 
(homologous to yeast Rpd3) comprise of HDAC1, -2, -3 and -8, which are widely expressed 
in many human tissues and cell lines. Among them both HDAC3 and HDAC8 can shuttle 
between the cytosol and the nucleus, while HDAC1 and HDAC2 are exclusively located in 
nucleus (Longworth & Laimins, 2006; Waltregny et al., 2004). The deacetylation of histones 
to repress gene transcription is the main function of class I HDACs. Class I HDACs form 
large multi-subunit complex that associates with transcription factors and other chromatin 
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modifiers, except HDAC8 whose function is not clearly clarified yet (X. J. Yang & Seto, 
2008). Recently, HDAC8 expression but enzyme activity was reported to mediate E-cadherin 
regulation(Choi et al., 2016). In mammals, HDAC1 and -2 can bind to each other forming the 
catalytic core of three different complexes: Sin3, nucleosome remodelling deacetylase and 
corepressor of RE1-silencing transcription factor. HDAC3 can form two different multi-
protein complexes, nuclear receptor corepressor and silencing mediator of retinoic acid and 
thyroid hormone receptors. Class I HDACs are mainly found in such nuclear complexes. 
Furthermore, the association with several different proteins show an essential role in 
regulating their activity, which is highly pronounced in developmental processes that requires 
a global modulation of transcriptional programmes. With the exception of HDAC8, knockout 
of class I HDACs in mice have indeed resulted in embryonic lethality (Haberland, 
Montgomery, & Olson, 2009). 
Class II HDACs can be divided into two sub-class groups. Class IIa members include 
HDAC4, -5, -7, -9, while class IIb comprises of HDAC6 and -10. Class II HDACs differ 
from Class I mainly for their tissue-specific expression pattern and the considerable lower 
deacetylase activity. Besides, their length (almost the double of Class I HDACs) and cellular 
localization are all different. Class II HDACs can shuttle between nucleus and cytoplasm, the 
activity of which is primarily regulated by its sub-cellular location in the cell, while 
phosphorylation by Ca
2+
 / CaMK (calmodulin-dependent kinase) at conserved serine residues 
promotes HDACs exporting them out of the nucleus (McKinsey, Zhang, & Olson, 2001). 
Mammalian class IIa HDACs (HDAC4, -5, -7, and -9) contain an N-terminal extension that 
interacts with other transcriptional cofactors and confers responsiveness to extracellular 
signals (Verdin, Dequiedt, & Kasler, 2003). They have conserved binding sites for the 
transcription factor myocyte enhancer factor 2 and the chaperone protein 14-3-3, which help 
HDACs shuttle from the nucleus to the cytoplasm. The nuclear-cytoplasm shuttling and 
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occurrence of post-translational modification such as phosphorylation, indicates their primary 
role as signal transducers in numerous tissues during development and disease (X. J. Yang & 
Gregoire, 2005). Class IIb family includes HDAC6 and HDAC10. HDAC10 presents a 
leucin-rich domain at the C-terminal. Recent reports showed HDAC10 might be up-regulated 
on human myeloma cell lines (Mithraprabhu, Kalff, Chow, Khong, & Spencer, 2014). 
HDAC6 is different from all other HDACs, as it harbours two deacetylase domains and a C-
terminal zinc finger, being the important cytoplasmic deacetylase in mammalian cells 
(Guardiola & Yao, 2002). Cytoskeletal proteins such as α-tubulin and cortactin, 
transmembrane proteins such as the interferon -α receptor, and chaperones are all targets of 
HDAC6 (Dregan, Charlton, Wolfe, Gulliford, & Markus, 2014; Zhang et al., 2007). Class-II 
HDACs display distinct tissue specificity. For example, HDAC4 is abundant in skeletal 
muscle and brain，whereas mHDAC5 is enriched in heart and mHDAC6 is expressed highly 
in testis (Verdel & Khochbin, 1999). Furthermore, recent study showed that mHDAC7 is 
most abundant in heart and lung and low in skeletal muscle. These observations suggest that 
these HDACs are not redundant, but rather, have distinct physiological functions (Kao, 
Downes, Ordentlich, & Evans, 2000). 
Class III HDACs comprise a group of protein called Sirtuins (SIRT1-7), which have been 
shown to promote cell survival by inhibiting apoptosis or cellular senescence in mammalian 
cells (Jung-Hynes & Ahmad, 2009). Although they possess a deacetylase domain, they 
diverge from classical HDACs as their enzymatic activity requires the cofactor NAD+. This 
feature suggests their involvement in metabolic functions (Longo & Kennedy, 2006). Among 
them, SIRT1 is the most well-characterized member and has been shown to be involved in a 
number of cellular processes, including gene silencing at telomere and mating loci, DNA 
repair, recombination, and aging (Longo & Kennedy, 2006). 
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HDAC11 is the latest discovered and the only member of Class IV HDACs, which has a 
catalytic domain at the N-terminal, indicating that HDAC11 may have a different more 
distinct function.(L. Gao, Cueto, Asselbergs, & Atadja, 2002). Recent study demonstrated 
that HDAC11, by interacting at the chromatin level with the IL-10 promoter, down-regulates 
IL-10 transcription in both murine and human APCs in vitro and ex vivo models (Chen et al., 
2016; Villagra et al., 2009). 
 
1.3.2 HDACs and EC differentiation    
In response to vascular injury, ECs migration and proliferation contribute to the repairing of 
the damaged EC or denuded endothelium. Recent reports show that circulating or local 
resident stem/progenitor cell differentiation is also involved in this process (Rinkevich, 
Lindau, Ueno, Longaker, & Weissman, 2011). Through modulating chromatin structures and 
non-histone transcription factors, HDACs are involved in the gene expression reprograming 
in multiple biological processes such as cell-cycle, cell differentiation and survival (Sata et al., 
2002) . Therefore, the involvement of HDACs in EC differentiation is expected. 
The first evidence came from studies with HDAC inhibitors (HDACi). HDACi decreases 
endothelial lineage commitment of endothelial progenitor cells (Iordache, Buzila, 
Constantinescu, Andrei, & Maniu, 2012; Rossig et al., 2005). Rössig L et al found that the 
suppressive effect of HDACi on EC differentiation was mediated by the down-regulation of 
homeobox transcription factor HoxA9, which directs the transcription of EC markers such as 
eNOS, VEGFR-2 and VE-cadherin, suggesting that the HDAC-dependent activation of Hox-
A9 is essential for EC differentiation(Rossig et al., 2005).  
There is no direct evidence that HDAC1, 2 and 8 are involved in EC differentiation, although 
indirect evidence indicates that HDAC1 may suppress EC differentiation. Rajasingh J et al 
showed that HDACs inhibitor, trichostatin A, improved AceH3K9 and reduced HDAC1 
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expression in bone marrow progenitor cells, leading to differentiation into myocytes and ECs, 
which suggests that HDAC1 plays a suppressive role in bone marrow progenitor cell 
differentiation toward EC lineage (Rajasingh et al., 2011). Different from other members 
within class I HDACs, accumulating evidence suggests that HDAC3 possesses a pivotal 
function in stem cells differentiation into ECs, which is capable of repairing the damaged 
endothelium. VEGF is a well-known EC differentiation inducer. Xiao et al reported that 
VEGF up-regulated HDAC3 in ESC-derived Sca1+ cells. Over-expression of HDAC3 via 
adenoviral gene transfer increased, while trichostatin A or HDAC3 siRNA abolished VEGF-
induced EC marker expression in Sca1+ cells, suggesting HDAC3 may function downstream 
of VEGF signal pathway (Xiao et al., 2006). Study from Illi B(Kajstura et al., 2005) et al 
demonstrated that laminar flow enhanced ESC-derived progenitor cell differentiation into EC 
lineage in an HDAC dependent manner. It was found that laminar flow stabilized and 
activated HDAC3 through the Flk-1-PI3K-Akt pathway in a ligand independent manner, 
which in turn deacetylated p53, leading to p21 activation, contributing to EC differentiation 
(L. Zeng et al., 2006). Similar mechanism is involved in VEGF-induced EC differentiation, in 
which HDAC3 modulates differentiation process via regulating non-histone proteins. Recent 
study found that unconventional splicing of HDAC3 might change HDAC3 function, 
inducing endothelial-to-mesenchymal transition (L. Zeng, Wang, et al., 2013). These reports 
suggest a critical role of HDAC3 in ECs fate determination. 
Class II HDACs seem not directly involved in EC differentiation. Several groups tried to link 
class II HDACs with ECs differentiation, but no solid evidence has been obtained. In 
Spallotta F et al’s reports, nitric oxide (NO) induced a cross-talk between class I HDACs 
(HDAC3) and class II HDACs (HDAC4 and 7), which might contribute to the 
neovascularization in ischemic tissue and skin repairing (Spallotta et al., 2013; Spallotta et al., 
2010). However, the effect of NO on EC differentiation may be largely derived from 
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HDACs-mediated global hypoacetylation on pluripotency maintaining genes like Oct4, 
Nanog, KLF4, etc. Considering class II HDACs have only weak deacetylase activity, the 
histone hypoacetylation might be mainly caused by HDAC3 in the complex. Reports from 
other groups indicate that HDAC7 may participate in EC proliferation and cell-to-cell contact 
but is not involved in EC differentiation (S. Chang et al., 2006; Margariti et al., 2010). A 
recent report from Song Y et al (Song et al., 2013) showed that AMPK activation participated 
in endothelial colony forming cells differentiation. During this process, HDAC5 could be 




HDAC7, as a member of the class II HDACs, is specifically expressed in the vascular 
endothelium during early embryogenesis where it maintains vascular integrity. Disruption of 
HDAC7 gene in mice results in embryonic lethality due to the rupture of blood vessels. In 
vitro study shows that HDAC7 is necessary for human umbilical vein ECs grown on Matrigel 
to form primitive vascular-like structures. Silencing of HDAC7 in ECs alters their 
morphology and motility and prevents their assembly into tube-like structures (S. Chang et al., 
2006).  There are still some conflicting reports concerning HDAC7 and EC proliferation 
(Margariti et al., 2010). Besides regulating angiogenesis, HDAC7 also play a role in 
apoptosis regulation. It is reported that mitochondrial and nuclear HDAC7 would redistribute 
to the cytoplasm upon induction of apoptotic cascade (Verdin, Dequiedt, & Kasler, 2004). 
Like other members of Class II HDACs, HDAC7 also shuttles between cytoplasm and 
nucleus. The export of HDAC7 from nucleus seems to be regulated by phosphorylation via 
protein kinase D (PKD) signalling pathway. VEGF is reported to do this. The consequence is 
that HDAC7-mediated suppression of gene expression is removed, leading to EC 
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proliferation and migration (Wang et al., 2008). Though it is widely recognized that HDAC7 
plays an essential role in ECs migration, the underlying mechanisms remain unclear. Some 
researches demonstrated that HDAC7 silencing inhibited EC migration and disturbed cell 
morphology via stimulating platelet-derived growth factor –B (PDGF-B) and its receptor 
PDGFR-β expression, partially responsible for the inhibition of EC migration (Mottet et al., 
2007). Zeng’s group previous studies have demonstrated that HDAC7 is involved in ß-
catenin signalling and cell cycle regulation. HDAC7 forms a complex with ß-catenin and14-
3-3 ε, ζ, η  proteins, therefore modulating the cellular localization of ß -catenin, the 
expression of  ß-catenin target genes and cell cycle–related genes. Overexpression of HDAC7 
retains ß-catenin in the cytoplasm, whereas HDAC7 deficiency increases nuclear 
translocation of ß-catenin. Overexpression of HDAC7 can ablate VEGF-induced ß-catenin 
translocation and EC proliferation. These findings suggest that HDAC7 is crucial in the 





1.4  Alternative splicing and alternative translation 
1.4.1 Alternative splicing 
RNA splicing is a modification of the nascent pre-messenger RNA (pre-mRNA) transcript in 
which introns are removed and exons are joined. Splicing takes place within the nucleus after 
or concurrently with transcription in nuclear-encoded genes. All of the typical eukaryotic 
messenger RNA (mRNA) must undergo splicing before it can be used to produce a correct 
protein through translation. The mechanism of RNA splicing is complicated and is done in a 
series of reactions which are catalysed by the spliceosome, a complex of small nuclear 
ribonucleoproteins (snRNPs), but there are also self-splicing introns (Figure 1.7). In brief, the 
spliceosome recognizes the splicing signals on a pre-mRNA molecule, and brings the two 
ends of the intron together. The branch-point binding protein (BBP) and U2AF, a helper 
protein that recognizes the branch-point site that is displaced by the U2 snRNP, forms base 
pairs with the branch-point site consensus sequence, while the U1 snRNP forms base-pairs 
with the 5' splice junction. At this point, the U4/U6-U5 "triple" snRNP enters the spliceosome. 
In this complex of snRNP, the U4 and U6 snRNAs are held firmly together by base-pair 
interactions but the U5 snRNP is more loosely associated. Then, U6 snRNP displaces U1 at 
the 5' splice junction through several RNA-RNA rearrangements and break apart of the 
U4/U6 base pairs. Thus, there is a type of RNA-RNA rearrangement in which the formation 
of one RNA-RNA interaction requires the disruption of another. Finally, accuracy of splicing 
is increased by checking and rechecking the RNA sequences before the chemical reaction is 




Figure 1.7 The RNA Splicing Mechanism 
  
RNA splicing is mainly catalysed by an assembly of small nuclear ribonucleoproteins 
(snRNPs) which constitute the spliceosome. The spliceosome recognizes the splicing signals 
on a pre-mRNA molecule, and brings the two ends of the intron together. BBP and U2AF 
form base pairs with the branch-point site consensus sequence, and the U1 snRNP forms 
base-pairs with the 5' splice junction. U4/U6-U5 "triple" snRNP enters the spliceosome. U6 
snRNP displaces U1 at the 5' splice junction through several RNA-RNA rearrangements and 
break apart of the U4/6 base pairs. In RNA-RNA rearrangement the formation of one RNA-
RNA interaction requires the disruption of another. 
 
During RNA splicing, exons are either maintained in the mRNA or targeted for removal in 
different combinations to produce a diverse array of mRNAs from a single pre-mRNA.  This 
process is known as alternative RNA splicing. Alternative splicing is one of the most 
significant components of the functional complexity in the mammalian genome. Alternative 
splicing gives rise to vast diversity over gene information resulted in different protein 
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isoforms in different tissues, developmental states, or disease conditions (Yabas, Elliott, & 
Hoyne, 2015). 
 
Figure 1.8  The process of  alternative splicing  
 
In DNA, the genetic information that includes the code for making a protein is located in 
fragments (exons, red boxes), which are interrupted by non-coding fragments (introns, green 
boxes). By the process of alternative splicing, the introns are removed and the exons spliced 
together in different combinations, generating different messenger RNAs (mRNA) that are 
decoded (translated) into distinct proteins. 
There are 5 basic types of alternative splicing:  
 Exon skipping or cassette exon: This is the most common mode in mammalian pre-
mRNAs, in which case, an exon may be spliced out of the primary transcript or 
retained.(Sammeth, Foissac, & Guigo, 2008). 
 Mutually exclusive exons: Only one of two exons is retained in mRNAs after splicing. 
 Alternative donor site: An alternative 5' splice junction (donor site) is used, changing the 
3' boundary of the upstream exon. 
 Alternative acceptor site: An alternative 3' splice junction (acceptor site) is used, 
changing the 5' boundary of the downstream exon. 
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 Intron retention: This is the least well understood, in which case a sequence may be 
spliced out as an intron or simply retained. These variants are believed to be largely 
derived from unspliced or partially spliced pre-mRNAs, which is distinguished from 
exon skipping because the retained sequence is not flanked by introns(Rio, 1991). If the 
retained intron is in the coding region, the intron must encode amino acids in frame with 
the neighboring exons, or a stop codon or a shift in the reading frame will cause the 
protein to be non-functional (Sammeth et al., 2008). 
 
Figure 1.9 Classification of basic types of alternative RNA splicing events. 
 
 Exon skipping, mutually exclusive exons, alternative 5’ donor sites, alternative 3’ acceptor 





Alternative splicing is a specific feature in eukaryotic species, which is regarded to be 
relative to genetic diversity within mammalian cells by increasing the number of protein 
isoforms that can be generated from one gene product. Through alternative splicing, different 
mRNA species can be derived from a single gene, giving rise to different protein variants 
with different even opposite functions (Pan, Shai, Lee, Frey, & Blencowe, 2008). 
 
1.4.2 Alternative translation 
Translation occurs in cytoplasm after the spliced mRNAs are exported form nucleus. ATG 
normally functions as the translation start codon, initiating nascent peptide synthesis by 
ribosome. However, recent studies have shown that translation of a peptide/protein can be 
also initiated from other codons within a single mRNA molecule, for example CTG initiates 
15% translation, giving rise to different peptide or protein variants, which is so-called 
alternative translation (Bazykin & Kochetov, 2011; Jackson, 2005). 
In addition to selecting different codons as start codon, there are multiple ATG codons within 
one mRNA molecule. These different ATG codons can serve as start codon as well, 
producing different peptides or proteins (Nemeth et al., 2007). Through alternative splicing, a 
single gene can produce different mature mRNA molecules. Through alternative translation, 
a single mature mRNA molecule can produce different peptides or proteins. The overall 





1.5 VEGF and VEGF signal pathway  
VEGF, originally known as vascular permeability factor (VPF), is a sub-family of growth 
factors, which is associated to tumor (Senger et al., 1983). Now they are normally regarded as 
important secreted glycoproteins, functioning in creating new blood vessels during 
embryonic development and after injury in which they accelerate re-endothelialisation and 
therefore enhance remodelling of injured arteries (Dvorak, Brown, Detmar, & Dvorak, 1995; 
Dvorak, Nagy, Feng, Brown, & Dvorak, 1999). 
The VEGF gene contains eight exons which are highly conserved in different species 
(Claffey, Senger, & Spiegelman, 1995). Each exon encodes domain with specific ability in 
binding different molecules. The first four exons encode the signal peptide, dimerization site, 
VEGF receptors (VEGF-R1 and VEGF-R2) recognition site and glycosylation site. Exon 5 
encodes the plasmin and matrix metalloproteinase (MMPs) cleavage sites. Eventually, exons 
6, 7 and 8 respectively encode for the heparin binding site, the neuropilin binding site and the 
unique VEGF sequence (Keyt et al., 1996; S. Lee, Jilani, Nikolova, Carpizo, & Iruela-Arispe, 
2005). The VEGF 5’- untranslated regulatory region (5'-UTR) control VEGF translation in 
different situations while 3’- untranslated region (3'-UTR) consists of multiple 
polyadenylation signals response to various stabilizing and destabilizing proteins (Figure1.10) 






Figure 1.10 Structure of VEGF exons.  
There are seven members in VEGF family: VEGF-A, VEGF-B, VEGF-C,VEGF-D, VEGF-
E(or virus-encoded VEGF-like proteins), VEGF-F( a series of snake venoms) and placental 
growth factor (PIGF) (Jussila & Alitalo, 2002). They contain a common structure of eight 
specific cysteine residues in a VEGF homology domain (H. Takahashi & Shibuya, 2005). 
VEGF-A was first discovered and mostly studied on cells of the vascular endothelium, which 
has reported to stimulate EC mitogenesis, cell migration and increases microvascular 
permeability.  
 
1.5.1 Alternative splicing and VEGF-A molecular diversity 
As mentioned before, alternative splicing is a regulated posttranscriptional process that leads 
to the production of several proteins by one gene. Alternative splicing of a single pre- mRNA 
gives rise to at least six different isoforms of VEGF-A: 121, 145, 165, 183, 189 and 206 
(numbers indicating the number of amino acid residues in each human polypeptide) (Fig 1.11) 
(Muller et al., 1997). These isoforms differ by the absence or presence of sequences encoded 
by exons 6 and 7, which alters their heparin-binding affinity and amino acid number (Cebe 
Suarez et al., 2006). VEGF-A121 does not bind to heparin or ECM while VEGF-A165 has 
moderate heparin binding ability. VEGF-A145 also contains a heparin binding domain that 
enable its binding to the ECM(Ferrara, Gerber, & LeCouter, 2003). VEGF-A189 and VEGF-
A206 bind heparin more strongly and are sequestered in the ECM and at the cell surface. 
VEGF-A121, VEGF-A145, and VEGF-A165 are secreted VEGF-A splice forms while the 
VEGF-A183, VEGF-A189 and VEGF-A206 are the matrix bound forms. Most VEGF-
producing cells express VEGF-A121, VEGF-A165, VEGF-A183 and VEGF-A189, but 
VEGF-A 145 and VEGF-A206 seem to be restricted to cells of placental origin  (Ferrara et 
al., 2003; Kofler & Simons, 2015; Roy, Bhardwaj, & Yla-Herttuala, 2006; Tammela, Enholm, 
Alitalo, & Paavonen, 2005). Recently, many researchers believe that there are two major 
VEGF subfamily isoforms: one is pro-angiogenic and the other is anti-angiogenic which 
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differ in the sequence of exon 8 that leads to two sub-exons termed exon 8a and exon 8b 
(Figure 1.11). These findings contributes to VEGF angiogenesis function that is the outcome 
of balance between pro-angiogenic and anti-angiogenic isoform activity(Bates et al., 2002; 
Seifi et al., 2012). 
 
Figure 1.11 Full-length VEGF gene and two families of VEGF-A isoforms.(Nowak et al., 
2008)  
 
1.5.2 VEGF and VEGFRs 
VEGF family growth factors form cysteine cross-linked dimers folded into a cysteine knot 
structure (Schlunegger & Grutter, 1992). Although structurally very similar, VEGF members 
have different physical and biological properties. They stimulate cellular responses by 
binding to different sites, times, and extents of specific tyrosine kinase receptors, 
immunoglobulin-like domains, a single transmembrane spanning region and an intracellular 
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portion containing a split tyrosine-kinase domain (Karkkainen & Petrova, 2000). VEGFRs 
can be grouped to three main subtypes, VEGFR-1 or Flt-1, VEGF-2, and VEGFR3. The first 
two receptors are expressed on vascular ECs, while the third one is expressed on lymphatic 
ECs (Holmes, Roberts, Thomas, & Cross, 2007).  
VEGF/VEGF-receptor system is a significant component in the process of angiogenesis that 
also contains many other stimulators, inhibitors and angiogenic modulators. Different VEGF 
variants bind with specific VEGFRs, inducing different biologic processes. VEGF-A binds to 
VEGFR-1 (Flt-1) and VEGFR-2 (Holmes et al., 2007). VEGFR-2 seems to be involved in 
almost all of the known cellular responses to VEGF. It is expressed in almost all ECs in 
mouse and human embryos, while its expression is reduced towards the end of gestation 
(Millauer et al., 1993). VEGFR-2 is effective in transducing signals regulating cell division 
and inhibition of cell death. Binding of VEGF-A to VEGFR-2 leads receptor dimerization, 
kinase activation and autophosphorylation of specific tyrosine residues within the dimeric 
complex, leading to EC survival, migration and differentiation and mediation of vascular 
permeability. VEGF increases vascular permeability by weakening endothelial cell-cell 
adhesion through changing in the phosphorylation of VE-cadherin and associated catenins. 
Moreover, when VEGF activates ECs, VEGFR-2 interacts with the VE-cadherin/catenin 
complex. The VE-cadherin/catenin complex is important for the above interaction, and in 
cases that ECs lack β-catenin or express a truncated mutant of VE-cadherin preventing the 
binding with β-catenin, VEGFR-2 fails to interact with the complex (Grazia Lampugnani et 
al., 2003). Therefore, cytoskeletal organization is the critical determinant of life or death for 
ECs, and adhesive interactions of transmembrane receptors linked to the cytoskeleton through 
junctional plaque proteins possess a functional role. In cases of targeted inactivation of 
VEGFR-2 gene, it is revealed as VEGF receptors (VEGFRs) on the cell surface, causing 
them activated through transphosphorylation. Therefore, one of the most important effects of 
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VEGFR-2 is probably in maintaining the survival and apoptosis balance, which is critical for 
vascular haemostasis and without which vasculogenesis is disrupted, resulting in embryonic 
death (T. Takahashi, Yamaguchi, Chida, & Shibuya, 2001).  
The role of VEGFR-1 in VEGF signalling is not clear yet, although recent studies indicate 
that it influences angiogenesis by recruiting monocytes and macrophages to sites of 
pathological angiogenesis, partially by stimulating differentiation of haematopoietic 
precursors (Jiang et al., 2002). The binding affinity of VEGF-A to VEGFR-2 is lower as 
compared with VEGFR-1, although the biological activities of VEGF-A are mainly 
transduced by VEGFR-2. So, VEGFR-1 is thought to act as an antagonist of VEGFR-2 which 
can sequester VEGF from VEGFR-2 binding, regulating vasculogenesis in the embryo 
(Karkkainen & Petrova, 2000). VEGFR-3 and its ligands VEGF-C and VEGF-D are 
important regulators of lymphangiogenesis, which mediates perpetual action and function of 








Interaction of VEGFs with VEGFRs. Colored arrows indicate major pathway. (Olsson, 
Dimberg, Kreuger, & Claesson-Welsh, 2006). 
 
 
1.5.3 Biologic effects of VEGFs  
VEGFs are crucial in embryonic development and in other physiological and pathological 
conditions, including wound healing, rheumatoid arthritis, ocular neovascularization, tumor 
progression, endometriosis and cardiovascular diseases (Roy et al., 2006).  
VEGF-A, a key molecule in induction of angiogenesis and vasculogenesis, causes 
proliferation, sprouting, migration and tube formation of ECs (Ferrara et al., 2003). VEGF-A 
was discovered as a vascular permeability factor secreted by carcinoma cell lines that 
stimulated the production of ascites and enhanced permeability in skin blood vessels (Senger 
et al., 1983). VEGF-A mediates its responses primarily by activating VEGFR-1 and VEGFR-
2. Overexpression of VEGF-A resulted in large, dilated and leaky vessels due to too strong 
angiogenic response (Bhardwaj et al., 2003). VEGF-A also causes vasodilatation by 
induction of eNOS and increasing NO production(Cooke & Losordo, 2002). VEGF-A 
promotes EC survival by inducing the expression of anti-apoptotic proteins B-cell lymphoma 
2 (Bcl-2) in the ECs, which might be related to the activation of phosphatidylinositol-3 kinase 
and Bcl-2 pathways (Bootle-Wilbraham, Tazzyman, Thompson, Stirk, & Lewis, 2001). 
Besides ECs, VEGF–A also play a role in other cell types. VEGF-A causes mitosis of retinal 
pigment epithelial cells and Schwann cells and promotes vascular SMC proliferation and 
migration (Gerber et al., 2002). VEGF-A is also reported to have hematopoietic effects on 
granulocyte-macrophage progenitor cells (Clauss et al., 1990). A number of signal 
transduction molecules are activated or modified in response to VEGF-A stimulation, such as 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and its downstream substrates, the 
serine / threonine kinase Akt 1, protein kinase B (PKB), PLC-y, the Scr family tyrosine 
kinases, the Ras GTPase activating protein, the small adaptor molecule Nck, focal adhesion 
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kinase C, extracellular signal-regulated kinase (ERK) and the p38 mitogen-activated protein 
kinase(P. Carmeliet, 2000; Claesson-Welsh, 2003; Gerber et al., 1998) (Figure1.13). The 
biological significance of all these interactions is not fully defined yet. However, Akt/PKB is 
critical in EC survival (H. Zeng, Sanyal, & Mukhopadhyay, 2001), and PLC-y-mediated 
activation of the ERK are crucial pathways in EC proliferation induced by VEGF.  
 
Figure 1.13 VEGF signalling pathways  
 
Most biologically relevant VEGF signalling is mediated via KDR. VEGF-dependent EC 
survival is mediated, in part, via PI3K through Akt kinase. Akt also causes Ca
2+
-independent 
eNOS activation through phosphorylation, an essential pathway for migration. Direct 
interactions between integrin avBj and KDR may also play a role in survival. PLC-y pathway 
is a major mitogenic signalling mechanism for VEGF resulting in PKC activation. PKC 
mediates activation of ERKs 112 via Raf-1 and MEK, and is involved in mitogenesis. Ca
2+
 
signalling is also important for eNOS activation and NO generation. 
 
The human VEGF-B gene is located on chromosome11, band q13 and contains eight exons. 
VEGF-B has two isoforms VEGF-B167 and VEGF-B186. VEGF-B might be related to 
formation of coronary collaterals. It was reported that deficient in VEGF-B resulted in 
development of smaller hearts and impaired recovery after induced myocardial infarction in 
mice (Bellomo et al., 2000). Also, VEGF-B knockout arthritis models showed reduced 
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synovial angiogenesis, suggesting an important role of VEGF-B in inflammatory 
angiogenesis (Mould et al., 2003). 
The VEGF-C gene consists of seven exons and located on chromosome 4q34. VEGF-C is 
activated in the extracellular space by proteases to create a homodimeric protein with both 
VEGFR- 2 and VEGFR-3 (Enholm et al., 2001). Developmental studies, knockout models 
and gene transfer experiments suggest that VEGF-C with VEGFR-3 is primarily functional 
on lymphangiogenic effects (Y. Li, He, Zhong, Li, & Liang, 2015; Morita et al., 2015). 
Besides, VEGF-C plays a crucial role in tumor lymphangiogenesis and lymph node 
metastasis (Hisamatsu et al., 2015; Jeltsch et al., 1997). 
The human VEGF-D gene is located on chromosome Xp22.31, which is a secreted 
glycoprotein that promotes growth of blood vessels and lymphatic vessels, and can induce 
remodeling of large lymphatics. The human VEGF-D binds to and activates VEGFR-2 and 
VEGFR-3, while the mouse VEGF-D binds only to VEGFR-3. VEGF-D is thought to have 
angiogenic ability both in vitro and in vivo. During embryonic development, VEGF-D 
deficient mice showed a lack of a profound lymphatic vessel defect (Baldwin et al., 2005; 
Jeltsch et al., 1997). Furthermore, VEGF-D has been proposed to have a role in tumor 
angiogenesis and lymphangiogenesis for its strong ability to induce angiogenesis in addition 
to lymphangiogenesis (Bates & Harper, 2002; Stacker et al., 2001). Thus, VEGF-D signaling 
is a potential target for novel anti-cancer therapeutics designed to explore anti-angiogenic 
approaches and to restrict metastasis (Achen & Stacker, 2012).  
Human PIGF gene, encoded by seven exons spanning an 800-kb-long DNA interval, has 
been mapped to chromosome 14q24. Four isoforms – PIGF-1, PIGF-2, PIGF-3 and PIGF-4, 
have been identified (Tjwa, Luttun, Autiero, & Carmeliet, 2003). PIGF-1 and PIGF-3 are 
diffusible isoforms, whereas PIGF-2 and PIGF-4 have heparin binding domains (W. Yang, 
Ahn, Hinrichs, Torry, & Torry, 2003). PIGFs mediate their effects mainly through VEGFR-1. 
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PIGF-2 (Yla-Herttuala & Alitalo, 2003) can also bind to neuropilin (NRP)-1 and -2 because 
of an insertion of 21 basic amino acids at the carboxyl terminus (Migdal et al., 1998; Persico, 
Vincenti, & DiPalma, 1999). PIGF has a major role in vasculogenesis and angiogenesis in 
human placenta. However its functions on the angiogenic role are inconsistent. Some studies  
reported that PIGF binding to VEGFR-1 failed to produce EC growth and angiogenesis, 
while others hold the view that PIGF/VEGFR-1 signaling promotes EC viability and 
angiogenesis (Roy et al., 2005). PIGF has direct effects on ECs, both by inducing its own 
signaling and by augmenting VEGF-driven angiogenesis (Autiero et al., 2003). 
VEGF-E was discovered in the genome of the parapoxvirus (Orf virus) that infects sheep, 
goats, and occasionally human (Lyttle, Fraser, Fleming, Mercer, & Robinson, 1994). 
Infection by this virus causes proliferative skin lesions in which extensive capillary 
proliferation. Besides, VEGF-E is reported to induce ECs proliferation, vascular permeability 
and angiogenesis in skin directly. And these biological functions are based on its interaction 
with VEGFR-2 and Nrp-1 (L. Wise, McCaughan, Tan, Mercer, & Fleming, 2007; L. M. Wise 
et al., 2003)  
VEGF-F, identified from snake (viper) venom, consists of two VEGF-related proteins 
designated as vammin (110 residues) and VR-1 (109 residues), which have a 50% primary 
structure identity with VEGF-A165 and bind selectively to VEGFR-2 (Suto, Yamazaki, 
Morita, & Mizuno, 2005). As its similar structure to VEGF-A165, VEGF-F exhibits a 
specific blockage of VEGF-A165 activity both in vitro and in vivo (Yamazaki, Tokunaga, 





1.5.4 VEGF signaling pathways in Angiogenesis  
VEGF is reported as an ECs selective mitogen, which is derived from arteries, veins and 
lymphatics. VEGF signalling pathways have been shown to play critical roles in development 
of the vascular system by regulating embryonic vasculogenesis, angiogenesis and 
arteriogenesis. In current study, we focus on angiogenesis. Angiogenesis is the process that 
new blood vessels takes shape from pre-existing post-capillary venules, where ECs respond 
to VEGF-A leading to sprouting, proliferating, and migrating to expand the vascular tree (P. 
Carmeliet & Collen, 1998). The molecular basis of angiogenesis in the embryo differs from 
that of pathological angiogenesis in the adult. Angiogenesis is an important mechanism of 
blood vessel formation in the adult (Bergers & Song, 2005). 
Angiogenesis initiates with vasodilation, a process involving NO. Vascular permeability 
increases in response to VEGF, which is regulated by the formation of fenestrations, 
vesiculo–vacuolar organelles and the redistribution of platelet endothelial cell adhesion 
molecule (PECAM)-1 and VE–cadherin, and involves Src kinases (Eliceiri et al., 1999).
 
Therefore, the increased permeability makes it possible for extravasation of plasma proteins 
that lay down a provisional scaffold for ECs migrating. For ECs migration, firstly they need 
to loosen inter EC junction and to relieve periendothelial cell support (Maisonpierre et al., 
1997). In this process, proteinases of the plasminogen activator, MMP, chymase or 
heparanase families influence angiogenesis by degrading matrix molecules and activating  
basic fibroblast growth factor (bFGF), VEGF and Insulinlike growth factor-1 (IGF-1) within 
the extracellular matrix (Coussens et al., 1999). Once the vessels become destabilized, 
proliferating ECs migrate to distant sites. During this process, VEGFs and VEGFRs have 
specific functions. For example, VEGF120 alone initiates angiogenesis but does not complete 
angiogenesis; VEGFR3 is involved in embryonic angiogenesis and pathological angiogenesis, 
whereas VEGF-C is angiogenic only in adult pathology; VEGF-B plays an important role in 
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coronary function after coronary occlusion (P. Carmeliet, Ng, et al., 1999; Dumont et al., 
1998). Then, ECs assemble and fuse with pre-existing vessels, allowing vessels to increase 
their diameter and length with VEGF121, VEGF165 and their receptors involved in. 
Furthermore, ECs become quiescent and survive for years, once assembled in new vessels. In 
the embryo endothelial survival depended on the interaction of VEGFs between VEGFR-2, 
β-catenin and VE–cadherin is very important, because reduced endothelial survival causes 
vascular regression (P. Carmeliet, Lampugnani, et al., 1999). According to different local 
physiological requirements, ECs acquire specialized characteristics and perform further 
remodelling and ‘pruning’ capillary-like vessels(Risau, 1998). 
（http://clinicalgate.com/cardiovascular-system-11/） 
Figure 1.14 Scheme illustrating vasculogenesis, angiogenesis, and assembly of the 
vascular wall. 
 
VEGFs and VEGFRs take part in all the process of vasculogenesis, angiogenesis and 
arteriogenesis. Angioblasts, initially expressing VEGFR-2 stimulated by VEGF-A to form the 
primary capillary plexus. Then competent ECs of the primary capillary plexus form vascular 
sprouts under additional stimulation by growth factors in the earliest stages of angiogenesis. 
This process followed by the recruitment of surrounding mesenchymal cells to form the 
cellular elements of the vascular wall.  
 
In the developed vascular system, angiogenesis and arteriogenesis continue to play important 
roles in both health and disease. In response to hypoxia or injury, VEGF promotes 
angiogenesis to create new capillary formation. In situations such as wound healing and 
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injury, hypoxic tissues secrete VEGF to induce angiogenesis by inducing EC sprouting, 
proliferation and migration, thereby expanding the capillary network and increasing nutrient 
and oxygen supply (Hoeben et al., 2004). Diseases characterized by vascular occlusion, such 
as coronary or cerebral artery occlusions, require to promote arteriogenesis to expand pre-
existing collateral anastomosis and induce new arterial growth, in which process VEGF 
signaling is also critical (Kofler & Simons, 2015). Understanding the VEGFs multiple 
function networks in angiogenesis and arteriogenesis is of great interest to develop targeted 
and more effective therapies for diseases characterized by inadequate blood flow. 
 
1.5.5 MEKK1 in VEGF signalling pathway 
Mitogen-activated protein kinases (MAPK), belonging to the CMGC (CDK/MAPK/GSK3/ 
CLK) kinase group, are protein kinases that are specific to the amino acids serine, threonine, 
and tyrosine. MAPKs are involved in cellular responses to mitogens, osmotic stress, heat 
shock and pro-inflammatory cytokines (Yujiri, Sather, Fanger, & Johnson, 1998). Mitogen-
activated protein kinase kinase kinase (MEKK) is a serine/threonine kinase that occupies a 
pivotal role in a network of phosphorylating enzymes. The cytoplasmic serine/threonine 
kinases transduce extracellular signals into regulatory events that impact cellular responses 
(Yujiri et al., 2000). An upstream mitogen or growth factor signal initiates a module of three 
kinases: MEKK that phosphorylates and activates a mitogen-activated protein (MAP) kinase 
kinase (MEK) and finally activation of MAP kinase (MAPK; e.g., ERK). Thus, this MAP3K-
MAP2K-MAPK module represents critical effectors that regulate extracellular stimuli into 
cellular responses, such as differentiation, proliferation and apoptosis all of which function 
during development(Craig, Stevens, Vaillancourt, & Camenisch, 2008).  
MEKK1, a key MAP3K, appears to transduce signals for activation of c-Jun N-terminal 
kinase (JNK) and extracellular signal–regulated kinase 1/2 (ERK1/2). It has been reported 
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that MEKK1 involved in cell migration regulation. MEKK1-knockout mice exhibit altered 
migration of epithelial cells resulting in defective eyelid closure. Apoptosis signal-regulating 
kinase 1 (ASK1), a proapoptotic member of the MAP3K family, acts as a target of bFGF-
mediated survival signaling in ECs (Alavi, Acevedo, Min, & Cheresh, 2007). MEKK1-
MKK1/MKK2-MPK4 mitogen-activated protein (MAP) kinase cascade also reported to 
represses cell
 
death and immune responses. MEKK1 translocates to the nucleus and acts as a
 
co-repressor with p53 to down-regulate PKD1 transcriptional activity (Islam et al., 2010). 
During blood vessel injury, several transcription factors are activated in response to hypoxia. 
Among these transcription factors, activator protein 1 (AP-1) is rapidly activated by hypoxia 
and triggers bFGF, VEGF, and tyrosine hydroxylase gene expression. MEKK1 dominant 
negative mutant inhibited AP-1 activity, deleted AP-1 binding sites within the c-jun protein, 
resulted in hypoxia response (Minet et al., 2001). 
The communication between integrin alphaVbeta3 (αvβ3) and VEGFRs acts to coordinate 
EC activity during angiogenesis (di Blasio, Droetto, Norman, Bussolino, & Primo, 2010). 
The cooperation between αvβ3 integrin and VEGF-A-mediated signals is one of the most 
relevant differences between VEGF-A and other angiogenic factors (Mahabeleshwar, Feng, 
Reddy, Plow, & Byzova, 2007). VEGF-A and integrin synergistically rescue angiogenesis in  
human microvascular ECs (Liu et al., 2003). It has been shown that VEGF-A regulates αvβ3 
integrin function by increasing the affinity of integrins for extracellular ligands (Byzova et al., 
2000). Besides, it is well documented that MAPK cascade is involved in ECs migration and 
immune response. Rangaswami H1 et al, reported that αvβ3 integrin mediated MEKK1 
phosphorylation and MEKK1-dependent c-Jun N-terminal kinases 1 (JNK1) phosphorylation 
(Rangaswami, Bulbule, & Kundu, 2005; Rangaswami & Kundu, 2007). However whether 




1.6 14-3-3 proteins and protein phosphorylation 
1.6.1 14-3-3 proteins  
14-3-3 proteins are a family of conserved regulatory molecules that are expressed in all 
eukaryotic cells, which are implicated in many cellular functions, including transcription, 
metabolism, and apoptosis (Dougherty & Morrison, 2004). They are small acidic proteins 
with a molecular mass ranging from 27 to 32 kDa (Aitken, Jones, Soneji, & Howell, 1995). 
There are seven identified 14-3-3 isoforms β, ζ, γ, η, ε, τ, and σ (stratifin/HME1) in mammals, 
which are highly conserved and tissue specificity(Rosenquist, Sehnke, Ferl, Sommarin, & 
Larsson, 2000).  
 
Figure 1.15 14-3-3 protein structure (Dougherty & Morrison, 2004) 
 
14-3-3s are phosphoserine-binding proteins. The binding may be regulated by factors that 
bind to the consensus motifs RSXpSXP and RXY/FXpSXP (Yaffe et al., 1997). Recent 
studies now indicate that the 14-3-3 binding interactions may be regulated by serine/threonine 
protein phosphatases PP1 and PP2A and 14-3-3 play an essential role in controlling the 
translocation of certain proteins from the cytoplasmic and endoplasmic reticulum to the 
plasma membrane (Jaumot & Hancock, 2001; Ory, Zhou, Conrads, Veenstra, & Morrison, 
2003). They play a central role in the phosphorylation-dependent regulation of diverse 
cellular processes for the ability to bind kinases, phosphatases, and transmembrane receptors. 
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14-3-3 protein phosphorylation is also believed to be associated with many diseases. In 
Parkinson's disease, increased 14-3-3 phosphorylation reduces neuroprotective potential of 
14-3-3 proteins and phosphorylation of 14-3-3s at serine 232 contributes to the 
neurodegenerative process (Slone, Lavalley, McFerrin, Wang, & Yacoubian, 2015). During 
intestinal inflammation, dysfunction of 14-3-3 function induced uncontrolled Akt activation 
(Akt Thr308 phosphorylation), nuclear Akt accumulation resulted in intestinal epithelial cell 
death(Gomez-Suarez et al., 2016).  Also, a lot of researches on cancer process indicate that 
the expression of 14-3-3 family members level is related to multiple tumor developing and 
suggest that it might be important to monitoring 14-3-3 levels during cancer treatment 
(Bergamaschi & Katzenellenbogen, 2012; Frasor et al., 2006; Z. Li, Liu, & Zhang, 2009; 
Matta, DeSouza, Ralhan, & Siu, 2010; Neal & Yu, 2010). 
 
1.6.2 Cellular function of 14-3-3 protein 
The 14-3-3 proteins exist in cells as homodimers and heterodimers and each molecule in the 
dimer contains an independent ligand-binding channel, thus a dimer can bind two pS/T sites 
on a single target or on separate binding partners at the same time (Gardino, Smerdon, & 
Yaffe, 2006). Binding of a 14-3-3 dimer can change the conformation of a target protein, 
mediate or prevent protein interactions and hide intrinsic localization motifs which may block 
the accessibility of a target protein to modifying enzymes such as kinases, phosphatases, or 
proteases. Therefore, 14-3-3 binding interactions can regulate the function of a wide spectrum 
of proteins with diverse biological activities. Multiple studies have been dedicated to 
understanding the role of 14-3-3 proteins in cell proliferation, migration, survival and 
apoptosis. 
Receptor tyrosine kinases (RTKs) is cell surface receptor which initiate normal cell 
proliferation. In RTK pathways, Raf proteins act as direct effectors of the Ras GTPase to 
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promote signaling through the ERK casade. Raf proteins contain at least two 
phosphorylation-dependent 14-3-3 binding sites, the role that 14-3-3 binding plays in Raf 
regulation is complex, largely due to the different sites: Binding of 14-3-3 to the N-terminal 
site plays a critical role in inhibiting Raf activation. However, during the Raf activation 
process, 14-3-3 binding to the N-terminal site is disrupted by dephosphorylation. 14-3-3 
serves a positive regulatory role in facilitating Raf dimerization via binding to the C-terminal 
sites to contact two Raf proteins (Garnett, Rana, Paterson, Barford, & Marais, 2005; Ritt, 
Monson, Specht, & Morrison, 2010). 
 
Figure 1.16 The function of 14-3-3 in Raf kinase regulation  
 
(A) In resting cells, a 14-3-3 dimer binds to phosphorylation sites found in the Raf N- 
terminal regions, maintaining Raf in an inactive state. (B) In response to proliferative signals, 
14-3-3 binding to the Raf C-terminal sites facilitates Raf dimerization in a Ras-dependent 
manner(Freeman & Morrison, 2011). 
 
Furthermore, Raf regulation is not the only role of 14-3-3 in RTK/Ras signalling. Another 
critical effector of RTK/Ras signaling is the PI3K/PDK/AKT cascade, and AKT is a key 
kinase that generates 14-3-3 binding sites on a diverse array of target proteins. Thus 14-3-3 







Figure 1.17 Signalling schematic for the Ras-Raf-MAPK and PI3K-Akt-mTOR 
pathways 
 
Remodeling of the actin cytoskeletion is involved in initiation of cell migration. At the 
leading edge of migrating cells, this remodeling is controlled by cooperation among Rho 
family GTPases, protein kinases and protein phosphatases. In the last few years, 14-3-3s were 
identified to bind with a great number of proteins involved in actin remodeling, and PKD has 
been shown as a kinase that generates 14-3-3 binding sites on several of these targets. Firstly, 
slingshot 1-like (SSH1L) the cofilin regulator, which are activated by F-actin binding and 
play a significant role in actin remodeling. The ability of SSH1L binding with F-actin is 
inhibited by the association of SSH1L with 14-3-3 (Huang, DerMardirossian, & Bokoch, 
2006; Nagata-Ohashi et al., 2004), which process is regulated by PKD (Eiseler et al., 2009; 
Peterburs et al., 2009). Moreover, cortactin the actin regulatory protein, is another recently 
identified PKD substrate that is regulated by 14-3-3 binding. Cortactin functions to enhance 
actin polymerization rates, which appears to be negatively regulated by 14-3-3 binding 
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(Eiseler, Hausser, De Kimpe, Van Lint, & Pfizenmaier, 2010). Besides, IRSp53, another 
molecule that involved in actin regulation, was identified as 14-3-3 binding partner. IRSp53 
contains multiple protein interaction domains and acts as a signaling platform to downstream 
actin regulatory proteins. 14-3-3 binding was found to terminate IRSp53 signaling and 
disrupt actin polymerization (Cohen, Fernandez, Lazaro-Dieguez, & Musch, 2011; Mackie & 
Aitken, 2005; Robens, Yeow-Fong, Ng, Hall, & Manser, 2010; Scita, Confalonieri, 
Lappalainen, & Suetsugu, 2008).  Above all, 14-3-3 binding acts to negatively regulate 
function in actin remodeling. 
 14-3-3 plays a major role in cell division cycle regulation. The association of 14-3-3 with its 
target proteins affects cell cycle progression through affecting protein localization or 
modification of their enzymatic activity. CDC25C was reported to activate the cyclin-
dependent kinase CDC2 which drives the cells through mitosis. During interphase, the 14-3-3 
isoforms γ and ε bind to CDC25C results in its inactivation, presumably by preventing the 
premature activation of CDC2 (Dalal, Yaffe, & DeCaprio, 2004). Moreover, 14-3-3γ 
regulates cell division mainly through interactions with cellular checkpoints proteins 
(Mhawech, 2005). 14-3-3γ regulates P53 by blocking its inhibitors and interacting with its 
regulatory proteins to regulate apoptosis (Jin et al., 2006).
 
14-3-3γ and ԑ are the only isoforms 
that bind to phospholipid aggregates in vesicles and membrane proteins. 14-3-3γ also 
interacts with organelle membrane of lysosomes, mitochondria, and Golgi.  During lysosomal 
accumulation, 14-3-3γ is enriched at the mitochondria and plays a role in mitochondrial 
quality control. 14-3-3γ interacts with large pleomorphic carriers that travel from the Golgi 
complex to the plasma membrane and undergo fission (Miyamoto et al., 2012; Valente et al., 





1.6.3 14-3-3 proteins and VEGF 
Clinical research found that 14-3-3 ζ, HIF-1a, and VEGF were involved in the same cascade 
of the malignant progression of gliomas (Cao et al., 2014). The expression levels of Mcl-1, 
VEGF-R2, and 14-3-3σ may be predicted to the early clinical response in head and neck 
tumor(Erovic et al., 2005). Our group’s previous study found that HDAC7 directly binds to 
β-catenin and forms a complex with 14-3-3 epsilon, ζ, and eta proteins, resulting in inhibition 
of EC growth and leading to G1 phase elongation. VEGF treatment abolished this inhibition 
by increasing HDAC7 degradation leading to the translocation of β-catenin to the nucleus to 
induces EC growth (Margariti et al., 2010). 
 
1.6.4 Protein phosphorylation 
Phosphorylation is the most common post-translational modification that occurs in both 
prokaryotic and eukaryotic organisms. Phosphorylation is the attachment of a phosphate 
group to a molecule. The new phosphorus group can activate, deactivate or change the 
function of the protein, which can regulate protein function without changing the amount of 
protein (C. Chang & Stewart, 1998; Cozzone, Grangeasse, Doublet, & Duclos, 2004).  It is 
estimated that 5% of the proteome contains enzymes that perform more than 200 types of 
post-translational modifications (Gonzalez-Montelongo, Marin, Perez, Gomez, & Diaz, 2013). 
These enzymes include kinases, phosphatases, transferases and ligases, which add or remove 
functional groups to amino acid side chains, and proteases, which cleave peptide bonds to 
remove specific sequences or regulatory subunits. Protein kinases play a role in a multitude 
of cellular processes, including division, proliferation, apoptosis, and differentiation. 
Phosphorylation usually results in a functional change of the target protein by changing 
enzyme activity, cellular location, or association with other proteins.  
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The catalytic subunits of protein kinases are highly conserved (Stout, Foster, & Matthews, 
2004) and eukaryotic protein kinases share a conserved catalytic core common with both 
serine/threonine and tyrosine protein kinases (Hanks & Quinn, 1991). There are a number of 
conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of 
the catalytic domain there is a glycine-rich stretch of residues near a lysine residue, which has 
been shown to be involved in ATP binding. In the central part of the catalytic domain there is 
a conserved aspartic acid residue which is important for the catalytic activity of the enzyme 
(Knighton et al., 1991). 
Phosphotransferase is a subclass of the transferases, comprising the enzymes that catalyze the 
transfer of phosphate group from a donor (usually high-energy) to an acceptor (specific 
substrates) (Burnett & Kennedy, 1954; C. Chang & Stewart, 1998; Cozzone, 1988; Stock, 
Ninfa, & Stock, 1989). Phosphorylation usually occurs on serine, threonine, tyrosine and 
histidine residues in eukaryotic proteins. However, in prokaryotic proteins phosphorylation 
occurs on the serine, threonine, tyrosine, histidine or arginine or lysine residues (Ciesla, 
Fraczyk, & Rode, 2011). Furthermore, phosphor-serine can transfer its phosphate group to 
serine or threonine. 
 
 




Enzyme-catalysed proton transfer from the (–OH) group on serine stimulates the nucleophilic 
attack of the γ-phosphate group on ATP, resulting in transfer of the phosphate group to serine 
to form phosphoserine and ADP. (—B:) indicates the enzyme base that initiates proton 
transfer. 
 
1.7 Hypothesis and aims of study 
Recently, a population of progenitor cells has been identified within the adventitia of the 
vessel wall. These cells are found to express progenitor markers including Sca-1, c-kit, CD34, 
CD90, CD73 and CD45 and are able to differentiate into SMC and ECs inresponse to 
different stimuli (Campagnolo et al., 2015; Wong et al., 2013). They play a reparative role in 
angiogenesis and repairing vascular injury. HDACs are known to play a central role in the 
regulation of gene expression, which direct key developmental processes such as cell 
proliferation, migration and differentiation. HDAC7, a member of HDACs family, plays a 
pivotal role in the maintenance of endothelium integrity. There are 8 splicing variants in 
mouse HDAC7 mRNAs. Within the non-coding area of some variants, there exists a short 
open reading frame (ORF). Whether these ORFs can be translated and their roles in cellular 
physiology remain unclear 
This project was originated from our previous finding supporting that one mouse HDAC7 
produced a 7aa peptide from the non-coding area, which contains a serine which can be 
phosphorylated. Herein we intend to confirm the translation of this 7aa peptide and its role in 
VPCs migration. The hypothesis of the present study is that HDAC7 derived 7aa peptide 
function as a phosphorylation carrier and promote VPCs migration. 
The aim of the present study:  
1. To verify that the 7aa peptide can be translated from the first ORF in ECs.  
2. To explore the role of 7aa peptide in phosphorylation transfer. Experiment Design： 
Firstly, detect the phosphorylation level of 7aa peptide with VEGF stimulate. Then, try to 
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find the upstream kinase and downstream effector of 7aa peptide based on proteomics study. 
Additionally, verify the signalling pathway of upstream kinase - 7aa peptide- downstream.  
3. To demonstrate the role 7aa peptide in VPCs proliferation, migration and differentiation 
towards EC lineage and attempt to demonstrated the underlying molecular mechanism. 
4. To explore the effect of 7aa peptide in angiogenesis in vivo. Matrigel plug assays to detect 
7aa peptide ability to induce angiogenesis in a mouse model. Injury mouse model and 
ischemia model to explore the 7aa peptide ability to promote angiogenesis and injury 
repairing.  
All above not only intent to confirm the existence of the alternative translation event but also 















2.1.1 Cell culture reagents 
All cell culture media and serum were purchased from Thermo Fisher Scientific (Waltham, 
MA, USA), while cell culture supplements and growth factors were purchased from Sigma 
(St Louis, MO, USA).  
2.1.2 Recombinant proteins 
The peptides of MEKK1 [SRRS(pSER)RIKAPSRNTC] and 14-3-3γ 
[KRA(pTHR)VVESSEKAYSC] were synthesized and used to raise anti-pMEKK1Ser393 
and anti-14-3-3γThr145 antibodies in rabbit by GenScript (Piscataway, NJ, USA). All 
peptides (see list in table 2.1) and DNA fragments were synthesized by GenScript. 
2.1.3 Antibodies and siRNA 
The antibodies against CD31 (ab28364), Sca1 (ab51317), 14-3-3γ (ab115176) and MEKK1 
(ab55653) were purchased from Abcam (Cambridge, UK). The antibodies against phosphor-
Serine (P5872), phosphor-Threonine (P3555), FLAG (F1804) and HA (H6908) were 
purchased from Sigma. The antibody against GAPDH (sc-25778) and siRNAs [control 
siRNA (sc-37007), MEKK1 siRNA (sc-35899) and 14-3-3γ siRNA (sc-29584)] were 
purchased from Santa Cruz (Dallas, Texas, USA). All secondary antibodies were from 
Dakocytomation (Glostrup, Denmark). All other chemicals were purchased from Sigma. All 



































2.1.4.1 General buffers 




10X Tris buffered saline (TBS) 




2.1.4.2 Cell lysis buffers 
WB （IP-A） 
 
1mM EDTA  
20mM Tris-HCl pH 7.5 
120mM NaCl 
1% Triton X-100 




2.1.4.3 Immunoprecipitation buffers 
IP-A 
 
1mM EDTA  
20mM Tris-HCl pH 7.5 
120mM NaCl 
1% Triton X-100 
1x protease inhibitor Cocktail (Roche) 
IP-B 
 
1mM EDTA  
20mM Tris-HCl pH 7.5 
120mM NaCl 
1x protease inhibitor Cocktail (Roche) 
IP Wash 
 
1mM EDTA  
20mM Tris-HCl pH 7.5 
120mM NaCl 
1% Triton X-100 
 
2.1.4.4 ELISA buffers 
PBS/T    1 x PBS  
0.01% (v/v) Tween 20 
Blocking buffer 1 x PBS 
 
1 x PBS 
2% (w/v) BSA 
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Substrate solution (phosphate citrate buffer) 50mmol/L phosphate-citrate, pH5.0 
 0.03% sodium perborate 
 0.17mg/ml O-Dianisidine dihydrochloride 
Stop solution 5M HCL 
                                               
2.1.4.5 SDS-PAGE and Western blotting buffers 
5x protein gel sample buffer β-Mercaptoethanol (5%) 
Bromophenol blue (0.02%) 
Glycerol (30%) 
SDS (Sodium dodecyl sulfate) (10%) 
Tris-Cl (250 mM, pH 6.8) 
Running buffer 25mM Tris/Base 
192mM Glycine 
0.1% (w/v) SDS 
Transfer buffer 25mM Tris/Base 
192mM Glycine 
20% (v/v) methanol 
pH 8.5 
Blocking milk solution 1 x TBS/T 
5% (w/v) skimmed milk (Tesco) 
Blocking BSA solution 
 
1 x TBS/T 




Stripping buffer(Re-blot) Purchased from Sigma 
 
2.2 Methods 
2.2.1 Cell Culture 
Vascular progenitor cells (VPCs) were isolated from the outgrowth of adventitial tissues of 
mouse arterial vessels as described previously (Iakovou et al., 2005). Briefly, the arterial 
vessels were harvested from C57BL/6J mice (Charles River, Margate, Kent, UK) and cut into 
2mm rings that were placed on gelatin-coated flasks and incubated at 37ºC in humidified 
incubator supplemented with 5% CO2 for 6hr. Stem cell culture medium [DMEM (ATCC, 
Rockville, MA, USA) supplemented with 10 ng/ml recombinant human leukemia inhibitory 
factor (LIF; Chemicon, Temecula, CA), 10% Fetal bovine serum (FBS, ATCC), 0.1 mmol/L 
2-mercaptoethanol, 100 U/ml penicillin, and 100 mg/ml streptomycin] were added and 
refreshed every other day until the cells reached 80% confluence. The cells were amplified 
and subjected to Sca-1+ cell purification using anti-stem cells antigen-1 (anti–Sca-1 ) 
immunomagnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of 
isolated Sca-1+ cells was confirmed using flow cytometry. The Sca-1+ VPCs were 
maintained in stem cell culture medium and split every other day. Up to 5 passages were used 
in this study.  
HEK293 cells were purchased from ATCC and maintained in DMEM (Thermo Fisher 
Scientific) supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 




2.2.2 Sca-1 Positive cell sorting 
As described in previous studies (X. Yang et al., 2006)，heterogeneous VPCs explanted 
from vein grafts were sorted using magnetic cell sorting kits (MACS) with anti-Sca-1 
immunomagnetic microbeads (Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany). 
According to the manufacturer’s protocol for the Anti-Sca-1 MicroBead Kit, the cultured 
VPCs were trypsinised and centrifuged at 300g for 10 minutes. Supernatant was removed 
completely and cell pellets were resuspended in 90 μl of cold buffer (phosphate-buffered 
saline (pH 7.2), 0.5% FBS and 2 mM EDTA) and 10 μl of Anti-Sca-1-FITC for at most 10⁷ 
total cells. The cells were then incubated in the refrigerator (4 °C) for 10 minutes. After 
adding 1−2 mL of cold buffer, the cells were washed and centrifuged at 300g for 10 minutes. 
The cell pellet was then resuspended in 80 μl of cold buffer with 20 μl Anti-FITC 
MicroBeads and incubated for 15 minutes at 4°C, followed by the same washing step as 
above. The cells were then resuspended in 500 μl of cold buffer and ready for magnetic 
separation. Briefly, a column filled with magnetic beads was placed in the magnetic field of a 
MACS Separator (Miltenyi Biotec). The column was rinsed with 500 μl cold buffer before 
applying the cell suspension. Unlabelled cells were passed through and collected for further 
analysis. After the column reservoir was empty, fresh 500μl cold buffer was added to the 
column and this washing step was performed 3 times. Finally, the column was placed in a 15 
ml collection tube and flushed with 1 ml cold buffer, by firmly applying the plunger, to 
harvest the magnetically labelled Sca-1+ cells. Sca-1+ VPC populations were expanded for 
up to 5 population doublings. 
 
2.2.3 VPC differentiation 
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 For VPC spontaneous differentiation, VPCs were seeded in fibronectin (Sigma, 5µg/ml)-
coated flasks in differentiation medium (alpha-MEM supplemented 10% FBS, 0.05mmol/L 
2-mercapotoethanol, 100 U/ml penicillin, and 100 mg/ml streptomycin) for three days with 
medium refreshment at 48hr. For EC differentiation, the 3-day spontaneously differentiated 
VPCs were subjected to serum free medium in the presence of 0.1ng/ml peptides with or 
without 5ng/ml mouse VEGF for 4 days. The medium was refreshed every other day. 
 
2.2.4 Adenoviral gene transfer 
A 1248 base pair DNA fragment corresponding to the first 1188 nucleotides of mouse 
HDAC7 transcript variant 2 (NM_001204276.1) with a FLAG and an HA tag inserted into 
the sORF and main ORF (225aa) respectively (Figure S1A) was synthesized and cloned into 
pShuttle2 vector, designated as pShuttle2-HD7FH. The resulting Ad-HD7FH vector was 
created accordingly by using the Adeno-X expression system 1 with the protocol provided 
(Clontech). The viral particles were amplified in HEK293 cells. For virus infection, the 
undifferentiated or 3-day spontaneously differentiated VPCs were incubated with Ad-null or 
Ad-mHD7FH virus at 10 multiplicity of induction in serum free medium containing 
0.05mmol/L 2-mercaptoethanol for 6hr, the virus containing medium was removed and fresh 
complete growth medium was added and incubated for 24hr, followed by further treatment 
and/or assessments. 
2.2.5 Immunofluorescence and histology 
2.2.5.1 Immunofluorescence staining of cells 
Cells were seeded at a density of 1x10
4
/well in 500μl culture medium in individual chambers 
of a 8-well chamber slide or cry-slide coated with 0.04% gelatine. After 24 hours, culture 
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medium was replaced with serum free medium. Following an overnight serum starvation, the 
cells were treated with relevant stimuli (details will be described in corresponding 
experiments) and then washed twice with PBS before staining. First the cells were fixed with 
4% paraformaldehyde (PFA) for 15 mins at room temperature and washed with PBS, before 
permeabilising with 0.1% Triton X-100 (Sigma-Aldrich) for 5 mins at room temperature. 
After washing with TBS 3 times, the cells were blocked with 5% normal serum (Dako) in 
PBS for 1 hour at room temperature. Incubation of cells with primary antibodies or blocking 
solution only (negative control) was performed at 4℃ overnight. The primary antibodies used 
and the dilutions in blocking solution for 1 hour. Then cells were washed with PBS 3 times, 
each time for 5 minutes. Secondary antibodies (Corresponding fluorescent-conjugated IgG 
antibodies were used as secondary antibodies (Invitrogen)) were applied on cells for 45 mins 
at 37℃ and protected from light. Following three 5 minute washes in the dark, the cells were 
counterstained with DAPI (1:1000 in PBS) for 2 minutes at room temperature. Images were 
taken by using SP5 confocal microscope (Leica, Germany), and were processed by Adobe 
Photoshop software. Magnification was indicated in figure legends as scale bars.  
 
2.2.5.2 Harvesting femoral arteries for histology 
Euthanasia was performed on each mouse using cervical dislocation. After death, a small 
incision was made in the right atrium to create an outlet for blood. The mouse was perfused 
slowly by injecting 20 ml of saline from left ventricle using a syringe with a 25 gauge needle. 
The clearing of blood in the liver served as an indicator of a good perfusion. Fixation was 
then performed by replacing saline with 10ml of 4% formaldehyde. The fixation tremors of 
the whole body were observed within seconds. An incision into the skin was made over the 
femoral artery, and the distal end of the injured artery was located by identification of the silk 
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suture for ligation. The artery was excised from surrounding tissues from the distal part, near 
the suture, to the proximal part, beside the abdominal aorta. The artery was then transferred 
into 4% formaldehyde solution at 4℃ for the further process of histology. For paraffin section 
preparation the fixed artery was transferred to 70% ethanol at 4℃ 24 hours before embedding 
in paraffin blocks. For preparation of frozen sections, dehydration of the fixed arteries was 
performed in 30% sucrose solution at 4℃ overnight followed by embedding them within 
Bright Cryo-m-Bed (Bright Instruments). The samples were then placed in liquid nitrogen for 
fast and adequate cooling before being cut into 5 mm thick sections. Frozen sections were 
stored at -20℃ before performing histological and immunofluorescence staining to assess the 
extent of injury and neointima formation. 
 
2.2.5.3 Immunofluorescent staining of frozen sections 
The slides containing frozen sections were thawed at room temperature for 30 minutes before 
staining. Rehydration of frozen sections was performed in PBS for 5 mins to remove tissue 
freezing matrix. To fix the tissue sections, the slides were immersed in pre-cooled acetone (-
20℃) for 10 min at room temperature. After briefly washing twice with PBS, the tissue 
sections were blocked with 5% normal donkey serum (Dako) in PBS for 1 hour at room 
temperature. Following removal of the block buffer, incubation of cells with primary 
antibodies or blocking buffer (negative control) was performed at 4℃ overnight in a 
humidified chamber. The slides were rinsed thrice in PBS, 5 mins each time before the 
application of appropriate secondary antibodies for 45 mins at 37℃ protected from light. 
Following repeated 5mins washes, tissue sections were counterstained with DAPI for 5 mins 
at room temperature. The slides were mounted with fluorescent mounting media (Dako) and 
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images were acquired using an Olympus IX81 microscope with Volocity software 
(PerkinElmer) or an SP5 confocal microscope with Leica LAS AF software. 
 
2.2.5.4 Haematoxylin and Eosin (HE) staining of frozen section 
The slides containing frozen sections were thawed at room temperature for 30 minutes before 
staining. The slides were first immersed in xylene for 10mins and this was then repeated in 
fresh xylene solution. Rehydration was then performed using the following concentrations of 
ethanol: 100% ethanol for two 5 minute immersions; 70% ethanol for one 5 minute 
immersion. The slides were washed briefly in tap water before H&E staining. After blotting 
excess water from the slides with paper towel, the slides were stained in haematoxalin 
solution for 5 mins, followed by washing under running tap water for 5 mins. Differentiation 
of the staining was performed by repeatedly dipping the slides into 1% acid ethanol 5 times. 
Subsequently, the slides were washed under running tap water for 5-10 mins and it was 
confirmed that the nuclei had turned blue under the microscope. Next, counterstaining with 
eosin solution was performed for 5 mins before dehydration. Following brief washing in 
water, the slides were immersed in first 70% ethanol and then 100% ethanol twice, 2 minutes 
for each step. The excess ethanol was blotted and dried before the slides were immersed in 
xylene twice, each time for 5 mins. Finally, the slides were mounted with xylene based DPX 






For ELISA performed on cells, the undifferentiated or 3-day differentiated VPCs were seeded 
in 96-well plated and treated as described in figure legends. The cells were fixed with 4% 
paraformaldehyde at room temperature for 10min, permeabilized with 0.1% Triton X-100 in 
PBS for 15min, treated with 3% H2O2 for 20min to quench endogenous horse radish 
peroxidase (HRP), blocked with 10% FBS/PBS for 1hr, followed by incubation with primary 
antibodies at 37ºC for 1hr and HRP-conjugated secondary antibodies at 37ºC for 45min. The 
associated HRP was revealed by incubation with phosphate citrate buffer (50mmol/L 
phosphate-citrate, pH5.0, 0.03% sodium perborate) containing 0.17mg/ml O-Dianisidine 
dihydrochloride and measured A405nm under Genios Pro-Tecan microtiter plate reader 
(GeniosPro, veco, USA). For ELISA on beads, the immunoprecipitation beads or biotin-
peptide pulldown assay beads were incubated with primary and HRP-conjugated secondary 
antibodies as described above with the A405nm measured on BioRad SmartpecTM Plus 
Spectrophotometer (Hercules, CA, USA). 
 
2.2.7 Immunoprecipitation and biotin-peptide pulldown assay 
The cells were lysed in lysis buffer [10mmol/L Tris-Cl pH 7.5, 120mM mmol/L NaCl, 1 
mmol/L EDTA pH 8.0, 1% Triton X-100 plus protease inhibitors (Roche)] by rotation at 4°C 
for 1hr. The protein concentration was measured with Bio-Rad reagent with protocol 
provided. For immunoprecipitation assay, one mg cell lysate was incubated with 2μg primary 
antibody or normal IgG and three volume of Triton X-100-free lysis buffer on a rotator at 
4°C for 2hr, and then 10μl Protein G-agarose beads (Sigma) was added and incubated for 
another 2hr, followed by PBS washing and ELISA assays. For biotin-peptide pulldown assay, 
5μg Biotin-labelled peptides were incubated with 50μg cell lysates and three volume of 
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Triton X-100-free lysis buffer at 37°C for 1hr, and then 10μl Streptavidin-agarose beads 
(Sigma) was added and incubated for another hour, followed by 6 times washing with lysis 
buffer containing 0.5% Triton X-100. The beads was incubated with 1xSDS loading buffer 
(10mmol/L Tris-Cl pH 7.5, 120mM mmol/L NaCl, 2% SDS, 5% glycerol, 0.025% 
Bromophenol blue, 1% 2-mercaptoethanol) 95℃, 5mins. The eluate was subjected to SDS-
PAGE, followed by Western blot or proteomics analysis. The beads were washed with lysis 
buffer containing 1% SDS for 6 times, followed by ELISA assay. 
 
2.2.8 In gel phosphorylation 
The Recombinant 14-3-3γ protein (H00007532-P01) was purchased from Novus Biologicals 
(Littleton, CO, USA). One hundred nanogram of 14-3-3γ protein was diluted in 250μl 0f 
1xSDS loading buffer and 25μl per lane of the diluted 14-3-3γ protein was applied to SDS-
PAGE. One lane together with the protein marker was cut and subjected to Silver staining 
(Thermo Fisher Scientific) with protocol provided. The 14-3-3γ protein bands in the 
remaining gel were cut and incubated in Novex Zymogram Renaturing buffer (Thermo Fisher 
Scientific) at room temperature for 1hr. After washing with TBST buffer (25mM Tris-Cl pH 
7.5, 120mM NaCl, 1 mM EDTA pH 8.0, 0.1% Tween 20) for 3 times, the gel bands were 
incubated in equeal volume of TBST containing 2ng/ml peptides at 37°C for 30min. The 
bands were re-organized and transferred to Hybond PVDF membrane (GE Health), followed 
by standard Western blot procedure. 
 
2.2.9 siRNA knockdown assay 
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The VPCs were sub-cultured 1:3 on fibronectin-coated 25ml-flasks in differentiation 
medium. Twenty four hours later, the cells were washed twice with and incubated serum free 
DMEM containing 0.05mmol/L 2-mercaptoethanol for 1hr. Ten μl of 10 μmol/L siRNA/flask 
was introduced into the cells with lipofectamine RNAiMax transfection reagent (Thermo 
Fisher Scientific) according to the protocol provided. The transfected cells were further 
cultured in stem cell medium for 72 hours, followed by VEGF treatment and migration 
assays. For EC differentiation assay, the transfected cells were cultured in serum free α-MEM 
medium in the presence of 0.1ng/ml peptides with/without 5ng/ml VEGF for 4 days, 
followed by EC marker analysis. During the EC differentiation, additional transfection with 
siRNAs was performed 48hr post the first transfection. 
 
2.2.10 Transwell chemotaxis assay 
The VPCs were harvested using trypsin/EDTA and subsequently seeded into the insert of the 
transwell unit with 8.0 micron pore membrane filters (Becton Dickinson Labware, USA) at 
5x104 cells/200μl of serum free medium. Eight hundreds of serum-free medium containing 
peptides (1ng/ml) with/without VEGF (5ng/ml) were added to the holder of the unit. PBS and 
1% BSA were used as control for peptides and VEGF respectively. Six hours later, the non-
migrating cells inside the inner side of the insert were carefully washed with PBS and 
removed using a cotton tip applicator. The VPCs on the outside of the filter membrane were 
fixed with 4% PFA for 15 mins before staining with 0.1% crystal violet solution at room 
temperature for 15 mins. The cells were observed under Nikon Eclipse TS100 microscope 
with Nikon Ph1 ADL 20x/0.4 lense and the images were taken using Nikon DS-Fil camera 
and Nikon Digital Sight System and processed by Adobe Photoshop software. Data was 




Figure 2.1 Layout of fields in each view of a transwell insert at 20x magnification 
 
2.2.11 Scratch wound healing assay 
VPCs were seeded in fibronectin-coated 12-well plates at 5x10
4 
cells per well in growth 
medium for 3 days with medium refreshment every other day. The cells would reach 
confluence after three days. Three horizontal x 2 vertical scratches were made using a 1ml 
pipette tip in each well. The wells were gently washed twice with PBS to remove cell debris. 
1ml serum-free medium containing 1ng/ml peptide or PBS was added in triplicate. Mark 6 
sites for image taking. The cells were observed under Nikon Eclipse TS100 microscope with 
Nikon Ph1 ADL 20x/0.4 lense and the images were taken using Nikon DS-Fil camera and 
Nikon Digital Sight System at 0hr, 12hr, 24hr and 36hr post-scratching, and processed by 
Adobe Photoshop software. Data was expressed as the mean percentage covered area by 
migrated cells in 6 fields of view x3.  
 
2.2.12 Quantitative reverse transcriptase-polymerase chain reaction 
Total cellular RNAs were extracted using RNeasy Mini kit (Qiagen, Manchester, UK) 
according to the protocol provided. One μg RNA was reverse transcribed into cDNA with 
random primers by MMLV reverse transcriptase (Qiagen). Using SYBR master mix (Thermo 
82 
 
Fisher Scientific) and Eppendorf MarsterCycler Cpgradient S (Eppendorf, Enfield, CT, 
USA), quantitative polymerase chain reaction was performed with 20ng of cDNA (relative to 
RNA amount) to amplify CD31, CD144 , SM22 and GAPDH.  
 




5>gga gtg cct tgt gga cat cag<3’ 
5’> tgc acg gtg acg tat tca ctc<3’ 
CD144 forward 
CD144 Reverse 
5’>gtg cct gaa gac atc cga gtg<3’ 
5’>gac ctc tgt cac tgg tct tgc<3’ 
SM22 forward 
SM22 Reverse 
5’>agt gga ttg tag tgc agt gtg<3’ 
5’> cag ttg gct gtc tgt gaa gtc<3’ 
GAPDH forward 
GAPDH Reverse 
5’>cat gtt tgt gat ggg tgt ga<3’  
5’>aat gcc aaa ctt ctc atg ga<3’ 
 
2.2.13 Western Blotting (WB) 
2.2.13.1 Whole cell protein extract preparation 
Whole cell extracts were prepared from VPC in order to investigate events involved in their 
intracellular signaling pathways using WB. Generally, 1-2x10
5
 VPC were washed with dPBS 
and lysed in 100μl IP-A buffer on ice for 10mins. Subsequently, lysates were collected into 
1.5ml eppendorf tubes (Appleton Woods, Birmingham UK), spun, and lysates without cell 
debris were transferred into new 1.5ml eppendorf tubes. Cell lysates were either stored at -
80°C or analysed. 
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2.2.13.2 Protein concentration measurement 
Protein concentration of cell lysates were measured using a BCA™ protein assay kit 
according to the manufacturer’s instructures. Firstly, 2μl of cell lysates were diluted with 8μl 
of dH2O before being transferred into a 96-well Maxisorb plate (Nunc, Denmark) in 
duplicates, alongside a series of BSA concentrations as standards. BCA solutions were mixed 
at a volume ratio of 50:1 (reagent A:B) before adding 200μl into each well and incubated for 
1 hr at 37°C. Absorbance was read at 710nm on a Multiskan Biochromatic™ plate reader 
using Ascent™.  
 
2.2.13.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
protein transfer 
Prior to SDS-PAGE samples were denatured by the addition of 5x gel sample buffer and 
subsequently boiled at 95°C for 5 mins. The denatured samples were loaded into a Nu-PAGE 
Bis-Tris gel  prior to electrophoresis for 2 hrs at a voltage of 120V for separation of proteins. 
Following separation with SDS-PAGE, the proteins can be transferred onto a membrane for 
identification with specific antibodies. The gel was placed on two layers of wet filter paper, 
followed by a polyvinylidene difluoride (PVDF) membrane that had previously been 
hydrated with 100% methanol and equilibrated in transfer buffer (Refer Section 2.1.5.5). The 
membrane was in turn overlaid with additional two layers of wet filter paper, and the 
assembly was subsequently placed into a transfer cassette (Invitrogin, U.K.). The transfer was 
carried out at a constant voltage of 35V for 1.5 hrs, in a tank (Biorad, U.K.) filled with pre-




2.2.13.4 Detection of proteins 
Following transfer, the membrane was blocked in 5% (w/v) instant skimmed milk powder in 
TBS/T for 1hr and washed 3x with TBS/T. Subsequently, the membrane was incubated with 
primary antibody in 5% (w/v) BSA or milk for 1hr at RT before washing again. The 
membrane was then incubated with a secondary HRP-conjugated antibody  in 5% (w/v) milk 
for 1hr at RT prior to detection using chemiluminescent substrate solutions, ECL™ or ECL™ 
plus. The protein bands were then visualised using Hyperfilm™. Membranes were usually re-
probed with new antibodies after removal of the previous one by treatment with 10mls of 
stripping buffer for 15 mins and re-blocking. 
 
2.2.14 Cell proliferation assays 
2.2.14.1BrdU incorporation assay  
The 3-day differentiated VPCs were treated different concentration of 7S or 7A peptides in 
the presence of 10ng/ml VEGF in serum free α-MEM medium for 24hr. The VPC 
proliferation assay was performed using a Cell Proliferation ELISA, BrdU (colourimetric) 
(Roche). BrdU labelling reagents (final concentration of 10 μM) were added 6hr prior to 
harvesting the cells for BrdU incorporation assays. After removing the labelling medium, 
200μl of Fix Denat was added in each well for 30 mins at room temperature. The solution 
was then removed thoroughly before incubating with BrdU conjugated antibody for another 
90 mins. After 3 washes with PBS, 100μl of substrate solution was added and incubated at 
room temperature. Once a change in colour was detected, 25μl of 1M H2SO4 was added to 
stop the reaction. The absorbance was measured at 450nm with correction at 690nm within 
5mins of adding the stop solution. A mixture of BrdU labelling solution and its antibody in 
culture medium was used as blank to identify the unspecific binding of BrdU and antibody to 
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the plate. The wells in which cells had not been incubated with BrdU but were incubated with 
antibody were used as background controls to evaluate the unspecific binding the antibody to 
VPCs. 
 
2.2.14.2 Limited dilution assays  
The VPCs were detached with trypsin and prepared as single cell suspension. The cell 
suspension was diluted to 10 cells/ml in normal culture medium and aliquoted into 96-well 
plates with 100μl/well cell suspension containing 1ng/ml peptides. The cells were cultured 
for 7 days with medium refreshment every other day. The peptides were maintained at 
1ng/ml for the whole process. The cells were then fixed with methanol (40%)/acetic acid 
(10%) and stained with Giemsa solution (Sigma). Colony formation was observed and 
calculated under microscope. Colonies with more than two cells (including two cells) were 
calculated.  The area of each colony was calculated with Adobe Photoshop software and 
presented as the average area occupied by each single cell. 
 
2.2.14.3 Clonogenic assay  
The VPCs were detached with trypsin and prepared as single cell suspension. The cell 
suspension was diluted to 50 cells/ml in normal culture medium and aliquoted into 6-well 
plates with 2 ml/well cell suspension containing 1ng/ml peptides. The cells were cultured for 





2.2.14.4 MTT assay 
The 3-day differentiated VPCs were seeded into fibronectin-coated 96-well plates in 
differentiation medium at 2x10
3
cells/well. Twenty four hours later, the cells were treated with 
serum-free medium containing 50μm and 100μm H2O2 in the presence of 1ng/ml peptides for 
24hr, followed by Methyl thiazolyl tetrazolium (MTT) assay with CellTiter 96 Queous One 
Solution Cell Proliferation Assay kit (Promega ) according to the manufacturer’s protocol. 
The absorbance at A490nm was measured on BioRad SmartpecTM Plus Spectrophotometer. 
PBS was included as control for H2O2 and peptides. Data was presented as relative A490nm 
with that of PBS control group set as 1.0.  
 
2.2.15  In vitro tube formation assay  
The procedure used was similar to that described previously (Kaufman et al., 2004). One 
hundred of cell suspension containing 4x10
4
 (total cell number) the 7-day differentiated 
VPCs was placed on top of the 50µl/well Matrigel (10 mg/ml; Becton Dickinson Labware, 
Bedford, MA, USA) in 8-well chamber slides (Nalge Nunc, Naperville, IL, USA). 
Rearrangement of cells and the formation of capillary-like structures were observed under 
Nikon Eclipse TS100 microscope with Nikon Ph1 ADL 20x/0.4 lense and the images were 
taken using Nikon DS-Fil camera and Nikon Digital Sight System at 8-18 hours and 
processed by Adobe Photoshop software.  Data was presented as mean of tube length of each 





2.2.16 In vivo experiment 
All animal experiments were performed according to protocols approved by the Institutional 
Committee for Use and Care of Laboratory Animals. 
2.2.16.1 In vivo Matrigel plug assay 
300µl of Matrigel containing 10ng/ml of 7A or 7S peptides or PBS were injected 
subcutaneously into the different sites in the back of each of the 12 C57BL/6J mice. The 
Matrigel plugs were harvested from the six mice sacrificed at day 7 and day 14 respectively 
post-inoculation and subjected to cry-sectioning, followed by immunofluorescence staining 
with anti-CD31 antibody. 
 
2.2.16.2 Femoral artery injury model 
The femoral artery injury model was introduced into ApoE-/- mice (Charles River) as 
described previously (Hu, Davison, Zhang, & Xu, 2003). The 100μl of 25% Pluronic-127 gel 
containing 10ng/ml peptide or PBS was applied surrounding the injured vessels. The injured 
vessels were harvested 4 weeks post-surgery and cryo-sectioned, followed by H&E and 
immunofluorescence staining. 
Mice were weighed and anaesthetised by intraperitoneal injection of ketamine (75 mg/kg; 
VetalarTMV, Pfizer) combined with medetomidine hydrochloride (1 mg/kg; Domitor®, 
Orion). A pinch test was performed on the tail of mouse to confirm that it was fully 
anaesthetised. Lubricating ointment was applied to the eyes of mice to prevent corneal 
desiccation. Hair was removed by application of a depilatory cream from both legs to lower 
abdomen. The mouse was then put on an aseptic operation board and covered with an aseptic 
drape. The depilated area of skin was sterilized with 70% ethanol and dried with sterile cotton 
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swabs just before surgery. An incision into the skin over the femoral artery was made before 
locating femoral artery by blunt dissection of surrounding tissues. The tissues were moistened 
periodically using saline for irrigation. The femoral artery was isolated by gently separating 
the femoral nerve and vein from the femoral artery, in sequence using micro-forceps. The 
anterior branch of the femoral artery was looped with a 10-0 silk suture before performing an 
arteriotomy using a 30 gauge needle at the distal part of the bifurcation. The opening of the 
arteriotomy was lifted with micro-forceps before a 0.25 mm guide wire (CROSS-IT 100XT, 
HI-TORQUE) was introduced into the artery until it could be inserted no further. The wire 
was inserted and retracted 5 times before it was allowed to remain in the femoral artery for 3 
mins. After gently and slowly removing the wire, the artery was immediately ligated. The 
same procedure was applied on the other femoral artery of each mouse. Then, 100 μl of 25% 
Pluronic-127 gel containing 1 ng/ml peptide or PBS was applied surrounding the injured 
vessels. The wound was closed after the matrigel had solidified. Anaesthesia was reversed 
with atipamezole hydrochloride (5 mg/kg; Antisedan, Orion) after surgery. Mice were 
allowed to recover in a warm container. In all experiments, mice were monitored 
continuously during recovery and periodically for 2 days. The injured vessels were harvested 
4 weeks post-surgery and cryo-sectioned followed by HE and immunofluorescence staining. 
 
2.2.16.3 Hindlimb ischemia model:  
The hindlimb ischemia model was performed in C57BL/6J mice as described previously (L. 
Zeng, Xiao, et al., 2013). The right femoral artery was ligated permanently, i.e. the femoral 
artery was ligated at two adjacent sites with the middle part cut. The 100μl of 25% Pluronic-
127 gel containing 10ng/ml peptide or PBS was applied surrounding the injured vessels. The 
foot blood flow was measured with LDI Doppler laser scanner (Moor Instruments, Devon, 
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UK) at 30min, 1 week and 2 weeks post-surgery. The reperfusion percentage was defined as 
the ratio of mean measurement in the foot area of ligated hindlimb to that of contralateral 
unligated hindlimb. The data was processed with Excel software. The flow image was 
processed with Adobe Photoshop software. The mice were sacrificed humanely after flow 
measurement at 2 weeks post-surgery. Adductor muscle tissues of ligated side were harvested 
and cryosectioned, followed by immunofluorescent staining with anti-CD31 and Sca1 
antibodies.  
2.2.17 Statistical analysis  
Data expressed as the mean±SEM were analyzed using GraphPad Prism 5 software with t-
test for pair-wise comparisons or analysis of variance (ANOVA), followed by Dunnett’s 
multiple comparison tests and significance was depicted by asterisks, *: p<0.05; **: p<0.01, 















3.1 HDAC7 transcript variant 2 undergoes alternative 





Different from prokaryotic species, the genetic information stored in a gene is discontinuous 
in eukaryotic species. The genetic information containing sequence is called exon, while the 
interrupting sequence is called intron. For most of the genes, the expression of a gene is 
derived the transcription from a unique promoter. However, some genes like HDAC7 have 
more than one promoter region, leading to alternative transcription selection.  After 
transcription, the nascent RNA molecules are called precursor RNAs from which the introns 
have to be excised, a so-called splicing event. Multiple different excision form may occur, 
which is called alternative splicing.  Alternative splicing is a specific feature in eukaryotic 
species. Through alternative transcription and/or splicing, different mRNA species can be 
derived from a single gene, giving rise to different protein variants with different even 
opposite functions.  
In general concept, a single mRNA molecule give rise to one peptide or protein via 
translation initiated from ATG codon. Actually, there are multiple open reading frames (ORF) 
with different size within a mRNA molecule. Whether only the main one can be translated 
remains unclear. Recent studies have shown that translation of a peptide/protein can be 
initiated from codons other than ATG. For example, CTG takes up to 15% translation. The 
selection of different ORFs or start codons is called alternative translation, which further 
increases diversity over gene information.  
Due to alternative tanscribed and  splicing, HDAC7 mRNA has 4 alternative splicing variants 
in human and  8 in mouse. Mouse HDAC7 mRNA transcript variant 2 (HDAC7-tv2) has a 
short open reading frame(sORF) before the main ORF that gives rise a functional HDAC7 
protein within the first 350 nucleotides in 5’ terminal area. These two ATG codons are 
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separated by about 120 nucleotides. The sORF gives rise to a 7-amino acids peptide, a very 
short open reading frame, which is followed by three sequential stop codons.  
3.1.2 Hypothesis and Aims 
Alternative translation could occur from the short open reading frame (ORF) which produces 
a 7-amino acids peptide (7A), a very short open reading frame in HDAC7-tv2. 
The aim of  this chapter is to verify that the 7aa peptide can be translated from the first ORF 






3.1.3.1 VEGF induces HDAC7 variants 2 transcription.  
In genetics, a promoter is a region of DNA that initiates transcription of a particular gene. 
Promoters are located near the transcription start sites of genes, on the same strand and 
upstream on the DNA(Gagniuc & Ionescu-Tirgoviste, 2013). HDAC7 mRNA can be 
transcribed from different promoters and undergo alternative splicing, giving rise to 4 
transcript variants in human and 8 in mouse.  In mouse, these 8 variants are derived from 
different promoters. HDAC7 - tv1, tv5, tv6 and tv7 are derived from promoter 1(P1), while 
HDAC7 – tv2, tv3, tv4 are from promoter 2(P2). In addition, the promoter of HDAC7– tv8 is 





Figure 3.1 Structure of HDAC7 mRNA variants.  
There are 8 transcript variants(tv) in mouse and 4 in human, which contain different promoter 
respectively. Mouse HDAC7 - tv1, tv5,tv6 and tv7 contain promoter 1(P1), while  HDAC7 – 
tv2, tv3, tv4 initiate transcription from promoter 2(P2). In addition, the promoter of HDAC7– 
tv8 is different from the others, so we define it as promoter 3(P3).  Human HDAC7-tv1, tv-3 
and tv-4 contain promoter 1(P1), and only HDAC7-tv2 initiate transcription from promoter 
2(P2). 
 
To identify the transcription source, we designed specific primers from exon 1s that are 
derived from different promoters and performed RT-qPCR. As shown in Figure 3.2, VEGF 
treatment increased transcription from promoter P2 but decreased from P1 in mouse 
differentiated VPCs, indicating that the transcription of HDAC7 undergoes a shift from P1 to 
P2 during the differentiation. 
 
Figure 3.2 VEGF increase Mouse HDAC7 promoter 2 transcription.  
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The 3-day differentiated VPCs were treated with 5ng/ml VEGF for 0,1,2,4,8,24 h separately, 
followed by RT-qPCR analysis of transcripts level from P1 and P2. Data presented are mean 
of three independent experiments. *: p<0.05.   
 
3.1.3.2 Alternative translation occurs from the first and second ORF within HDAC7 
mRNA 
Normally, translation of an mRNA initiates from the first ATG start codon. However, the 
translation is also initiated from the second or third start codon.  As described in introduction, 
in the 5’ untranslated region (UTR) of mouse HDAC7-tv2 (HDAC7U), there is a short ORF 
(sORF) encoding a 7aa peptide with three cascade in-frame stop codons. This HDAC7 
mRNA exists in mouse ESCs and ECs. When the ESCs are induced to differentiate toward 
smooth muscle cell lineage, a 57 nucleotide sequences will be excised from the mRNA, 
within which the three stop codons are removed. The two open reading frames are joined 
together, giving rise to a bigger HDAC7 with 22 amino acids more (HDAC7F, F for fully 
spliced). The 7 amino acid peptide becomes the far N-terminal end of the bigger HDAC7 
protein (Figure 3.3A). During the previous study on HDAC7 and SMC differentiation 
(Margariti et al., 2009), we compared the effect of different HDAC7 variants on EC marker 
expression. Theoretically, HDAC7U and HDAC7S should have a similar effect, as they both 
express the same HDAC7 protein. However, Over-expression of HDAC7U had less 
suppressive effect on EC marker expression as compared to HDAC7S although both variants 
expressed the same amount of HDAC7 proteins, suggesting that the non-translated area may 
give rise to a 7-amino acid (7aa) peptide from the first open reading frame (ORF). To test this, 
synthesized 7aa peptide (7A) was added to HDAC7S transfected cells and a scrabbled 7aa 
peptide (7S) was included as control. As shown in Figure 3.3B, addition of the peptide 7A 
reversed the inhibitory effect of HDAC7S, even increased EC marker expression. These 
results suggest that 7A peptide may be translated from the first ORF.  However, the 
difference of EC marker expression might be from the plasmid itself, so HDAC7 protein 
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level should be measured in HD7U and HD7S transfected cells, which will explore in future 
work. 
 
Figure 3.3 7A induces EC marker expression.  
(A) A schematic illustration of the partially spliced HDAC7 (HD7u) and short HDAC7 
(HD7s). The mRNA sequence of the 5’ non-coding area in HD7u was shown in orange box 
and red characters with the short ORF underlined. The main ORF was shown in brown 
characters and box. ATG stands for start codon, TAG, TGA and TAA stand for stop codons. 
(B) Inclusion of synthetic 7aa-peptide (7A) could reverse the suppressive effect of HD7s on 
EC marker transcription.  Embryonic stem cells were transfected with EC marker gene firefly 
luciferase reporter together with pShuttle-HD7u (HD7u), or pShuttle-HD7s with/without 7A. 
pShuttle2 empty vector was included as control (mock). Renilla-luc was included as internal 
control.  RLU was defined as the ratio of firefly luciferase activity to that of Renilla 
luciferase with mock control set as 1.0.  Data presented are mean of three independent 
experiments. *: p<0.05.  
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These findings suggest that the ATG start codon in sORF may initiate translation. Therefore, 
we wondered whether the sORF could be translated alone. As a peptide with only seven 
amino acids was not easy to be detected by routine methods, we created an artificial construct 
containing the whole 5’UTR and 225aa of the main ORF, designated as pShuttle2-HD7FH 
(Figure 3.4 A). In this plasmid, a FLAG tag was inserted upstream of the stop codon in sORF 
and an HA tag was fused to the 225aa of the main ORF. The expression of FLAG and HA 
can reflect the translation of short and main ORFs respectively. A 800 base pair DNA 
fragment containing Flag and HA sequences within the first and second ORF respectively 
was synthesized and cloned into pUC57 vector by Invitrogen. The band of interest DNA 
fragment released by restriction digests is shown on Figure 3.4B. The DNA fragment was 
then subcloned into the NheI/XbaI site of pShuttle2 vector, and then Ad-mHDAC7FH vector 
was created by using Adeno-X expression system 1 and viral particles were prepared with the 





Figure 3.4 Constructure of pShuttle-HD7u-FLAG-HA vector (HD7-FH). 
(A) A schematic illustration of pShuttle-HD7u-FLAG-HA vector (HD7-FH). A FLAG (bold 
green) and HA (bold red) sequence was inserted into the short (underlined) and main ORF 
(blue, 225aa downstream start codon), respectively. A TAG stop codon was included 
downstream of HA tag. (B) DNA fragment containing Flag and HA sequences released by 




Double immunofluorescence staining detected FLAG and HA within a single cell will give us 
information on whether translation is initiated from the sORF or main ORF.  In Ad-HD7FH-
infected VPCs, both Flag and HA staining can be detected, indicating that the sORF indeed 
can be translated. ELISA with anti-FLAG and anti-HA antibodies revealed that VEGF might 
induce the translation shift from the main ORF to sORF, as the ratio of FLAG to HA tag was 
significantly increased in response to VEGF-treatment (Figure 3.5).  
                         
                                                                                                                           
Figure 3.5 VEGF increased the 7aa-peptide translation. 
(A) The short open reading frame in the 5’ non-coding area could be translated in VPCs as 
revealed by immunofluorescence staining of 7aa-peptide-FLAG fusion peptide in pHD7-FH 
vector transfected VPCs. (B) VEGF increased FLAG-tagged 7aa-peptide expression. FLAG 
and HA expression was detected by ELISA in pHD7-FH vector infected 3-day spontaneously 
differentiated VPCs (dVPC). VPC: undifferentiated VPCs. 1% BSA was included as vehicle 
control. Data presented are representative images or mean of three independent experiments. 




As descried above, 7A can be translated from the sORF and enhance EC marker expression 
during the differentiation of ESCs. To test whether this 7A has pro-angiogenesis effect, 
Matrigel plug assays were performed in C57BL/6J mice via subcutaneous implantation of 
peptide-containing Matrigel, followed by observation of CD31 positive cells in plug section 
harvested at day 7 and 14 post-implantation. At day 7 post-implantation, very few CD31 
positive cells could be observed in PBS group, and only a few CD31 positive cells but no 
capillary structures were present in 7S group. In contrast, several capillary structures could be 
observed in 7A group. At day 14 post-implantation, only a few CD31 positive cells and 
capillary structures could be observed in both PBS and 7S groups, but multiple capillary 
structures were observed in 7A group (Figure 3.6). These results suggest that 7A peptide can 
indeed induce angiogenesis in vivo. 
 
    
Figure 3.6 The 7aa-peptide increased angiogenesis in vivo.  
The 7A peptide induced CD31 positive capillary vessel formation in Matrigel plug implanted 
subcutaneously in C57bl/6 mice. Left panel shows CD31 staining on Matrigel plug sections 
harvested at 1 week (1W) and 2 weeks (2W) post-inoculation. Right panel shows the average 
CD31 positive cells/20x view from 6 plugs for each peptide. PBS was included as control. .  
Data presented are representative images or mean of three independent experiments. *: 





For transcription to take place, the enzyme that synthesizes RNA, known as RNA polymerase, 
must attach to the DNA near a gene. Promoters contain specific DNA sequences such as 
response elements that provide a secure initial binding site for RNA polymerase and for 
proteins called transcription factors that recruit RNA polymerase. These transcription factors 
have specific activator or repressor sequences of corresponding nucleotides that attach to 
specific promoters and regulate gene expression(Gagniuc & Ionescu-Tirgoviste, 2013). In 
eukaryotes, transcription is more complicated than in bacteria, in part because eukaryotes 
have the three classes of RNA polymerase that transcribe different sets of genes. Promoters 
represent critical elements that can work in concert with other regulatory regions (enhancers, 
silencers, boundary elements/insulators) to direct the level of transcription of a given gene. In 
eukaryotes, the "core" promoter for a gene transcribed by pol II is most often found 
immediately upstream (5’) of the start site of the gene(Smale & Kadonaga, 2003). Most pol II 
genes have a TATA box (consensus sequence TATTAA) 25 to 35 bases upstream of the 
initiation site, which affects the transcription rate and determines location of the start 
site(Gagniuc & Ionescu-Tirgoviste, 2012).  
In mouse, HDAC7 mRNA has 8 transcript variants which are derived from different 
promoters. HDAC7 - tv1, tv5, tv6 and tv7 use P1, while HDAC7 – tv2, tv3, tv4 are 
transcribed from promoter 2 (P2).  VEGF induced P2 transcription in differentiated VPCs, 
indicating that VEGF might promote tv2 translation to produce more 7 amino acid which 
only exists on P2 tvs. Then the further experiment verified that VEGF not only influence the 
transcription of HDAC7 but also regulate its translation level with increasing the sORF 
translation to produce more 7aa-peptide. For the translation initiation, ribosome assembles 
around the target mRNA. Eukaryotic ribosomes are known to bind to transcripts in a 
mechanism unlike the one involving the 5' cap, at a sequence called the internal ribosome 
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entry site ( IRES). Ribosome recruitment happens when eukaryote initiation factors elF4F 
and poly(A) binding protein (PABP) recognize the 5' capped mRNA and recruit the 43S 
ribosome complex at that location. Following recruitment of the ribosome, translation 
initiation happens at the start codon found within the Kozak consensus sequence ACCAUGG 
(Kozak, 1987). Since the Kozak sequence itself is not involved in the recruitment of the 
ribosome, it is not considered a ribosome binding site (Hellen & Sarnow, 2001). In HDAC7 
mRNA we found the main ORF contains a Kozak sequence which might results the 
translation skipping. VEGF increases sORF translation may via disturbing the recognition of 
the Kozak sequence in main ORF or recruit specific factors in upstream of sORF, and we will 
explore in the further work. 
Our previous study revealed that VEGF suppressed HDAC7 transcription and induced a rapid 
and transient degradation of HDAC7 (Margariti et al., 2010). Our group previous study 
demonstrated that VEGF treatment rapidly decreased endogenous HDAC7 protein via protein 
degradation, while U73122 and IP3 partially block VEGF-induced HDAC7 protein 
degradation, which indicate that VEGF induces HDAC7 degradation through the PLCγ-IP3K 
signal pathway. However the mechanism of VEGF suppressed HDAC7 transcription was still 
unknown. Herein, we found that VEGF regulates HDAC7 transcription by suppressing 
Promoter 1 transcription. Thus, we postulated that VEGF suppressed HDAC7 transcription 
might through decreasing HDAC7 promoter 1 variants transcription. Furthermore U73122 
and IP3 only partially block VEGF-induced HDAC7 protein degradation, decreased HDAC7 
protein might be partially due to the shift translation from HDAC7 protein to 7aa-peptide as 
well. 
As there is no commercially available way to detect a 7aa peptide, we created a mutated 
HDAC7 construct mHD7-FH, in which a Flag tag was inserted into the first ORF exactly up-
stream of the stop codon and an HA tag was inserted into the second ORF. We choose Flag 
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and HA tag not GFP and YFP which can measure directly. For 7 amino acid is very short, 
GFP or YFP are much longer than 7amino acid, which probably introduce artificial results. 
Flag and HA tag is relatively small, therefore we choose them to make the results reliable. As 
we transfected the plasmid to VPCs, both of the HA and the Flag signal were very low. For 
the progenitor cells are difficult to transfect or infect. So VPCs undergo 3 days spontaneously 
differentiation before the transfection. The Matrigel model staining results showed that 7A 
can promote angiogenesis. However, how does 7A increase angiogenesis? There are at least 
two hypothesizes: 7A induce progenitor cell migrate to matrigel and differentiated to EC to 
form capillaries; 7A directly induce EC migrate to matrigel. As far as we know, both of them 
occurred during the 7A induced angiogenesis.   
 
3.1.5  Conclusions 
In summary, this study confirmed that VEGF induced HDAC7 mRNA underwent alternative 
transcription and translation. Alternative translation occurs from the first and second ORF 
























VEGF comprises several isoforms which bind to different receptors and promotes 
angiogenesis through activation of specific kinase cascade, such as MAP kinase pathway and 
so on. Though activation of different signal pathway regulates variety field of angiogenesis, 
the common feature of all the VEGF signal pathways is phosphate transfer. 
The sORF encodes a 7aa-peptide (7A, MHSPGAD), which contains a serine that is one of the 
four amino acids that can be phosphorylated. Furthermore, the phosphate on serine can be 
transferred to a serine or a threonine residue. We wonder whether the serine within 7A can be 
phosphorylated.  If so, does it play a role in VEGF signal transduction via phosphate transfer? 
In this chapter, we identified 7A functioned as a phosphate carrier on in the MEKK1-7A-14-
3-3γ signal pathway. MEKK is a serine/threonine kinase that occupies a pivotal role in a 
network of phosphorylating enzymes. MEKK1, a member of MEKK, was reported to be 
involved in cell migration regulation. 14-3-3s, phosphoserine-binding proteins, are a family 
of conserved regulatory molecules that are expressed in all eukaryotic cells, which are 
implicated in many cellular functions, including transcription, metabolism, and apoptosis.  
 
3.2.2 Hypothesis and Aims 
We hypothesis that 7A functioned as a phosphate carrier, and receive phosphate group from 
upstream kinase and transfer the phosphate group to downstream target protein. 
The aim of this chapter is to explore the role of 7aa peptide in phosphorylation transfer. 
Firstly, detect the phosphorylation level of 7aa peptide with VEGF stimulate. Then, try to 
find the upstream kinase and downstream effector of 7aa peptide based on proteomics study. 





3.2.3.1 VEGF induced 7aa-peptide phosphorylation via MEKK1 
To test this, we performed immunoprecipitation assay with anti-FLAG antibody, followed by 
ELISA with anti-phosphoserine antibody. As shown in Figure 3.7A, serine phosphorylation 
was detected in Ad-HD7FH-infected VPCs as compared to control virus infected cells, which 
was significantly increased by VEGF treatment. Considering the phosphorylation signal 
could be derived from FLAG-tagged 7A or its associated proteins, we performed a special 
biotin-labelled peptide pull-down assay (Figure 3.7B). These experiments demonstrated that 
the serine residue in 7A was indeed phosphorylated and the phosphorylation could be 
enhanced by VEGF treatment, and that this phosphorylation was sequence specific as the 
serine residue in the scrabble 7aa-peptide (7S, MPHASGD) was not phosphorylated (Figure 














Figure 3.7 VEGF increase 7A phosphorylation 
(A)VEGF increased FLAG-tagged peptide phosphorylation. The 3-day differentiated VPCs 
were infected with Ad-null or Ad-HD7FH virus at 100MOI and incubated in differentiation 
medium for 48hr. The cells were then treated with 10ng/ml VEGF for 30min, followed by 
immunoprecipitation with anti-FLAG plus ELISA with anti-phospho-serine antibody. 1% 
BSA was included as vehicle control. Relative A405nm was defined as ratio of the A405nm 
value with that of Ad-null/BSA group set as 1.0. (B) A schematic illustration of 
peptide/protein binding assay. Biotin-labelled peptides (B-7A) were incubated with cell 
lysate. The peptide/protein complex was pulled down by streptavidin beads. The associated 
proteins were eluted with SDS solution and subjected to Western blot or proteomics analysis. 
(C) The 7aa-peptide was phosphorylated in cell free system. Phospho-Serine in streptavidin 
trapped Bio-peptides was detected by ELISA. The beads were subjected to ELISA with anti-




To identify the potential upstream kinase for 7A phosphorylation, we performed a pilot 
proteomics analysis of the peptides-associated proteins, especially on their phosphorylation 
changes in response to VEGF treatment. We detailed phosphorylation changes on kinase and 
found that 7Ap (the phosphorylated on serine residue of 7A) and V+7A bind much more 
kinase than others. While 7Aa and 7Aa+VEGF bind phospho-MEKK1 (p-MEKK1) 
specifically (Table 3.1).  Based on the proteomic results, we supposed MEKK1 as upstream 
kinase for 7A phosphorylation. As 7Aa cannot be phosphorylated, when 7Aa bind to p-
MEKK1, it would prevent the phosphate group transfer, resulting in accumulation of p-
MEKK1.  
 
Table 3.1                                    Biotin-peptide binding Phosph-kinase 
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kinase catalytic subunit alpha-1  
        574 
6-phosphofructo-2-
kinase/fructose-2, 6-
bisphosphatase 2 variant 4  
       45
1 
 
6-phosphofructokinase type C          232 
6-phosphofructokinase, liver 
type  
  13  99    211 
AarF domain-containing 
protein kinase 4 
    16     
Beta-adrenergic receptor kinase 
1 (Fragment)  




inhibitor 2A, isoform 3  
        173 
DNA-dependent protein kinase 
catalytic subunit  
    13     
Dual-specificity testis-specific 
protein kinase 2 
       91  
Hexokinase 1, isoform CRA_f         18  
Hexokinase-2      81   10
3 
 




protein kinase 4  
    23     
Isoform 2 of ADP-dependent 
glucokinase  
       95  
Isoform 2 of Cyclin-G-
associated kinase  
       83  
Isoform 2 of Inactive serine/ 
threonine-protein kinase 
TEX14 
   15      
Isoform 2 of Mitogen-activated 
protein kinase-binding protein 
1 
      61   
Isoform 2 of Rho-associated 
protein kinase 1  
       31  
Isoform 2 of Traf2 and NCK-
interacting protein kinase  
    20    70 
Isoform 3 of A-kinase anchor 
protein 9  
        61 
Isoform 3 of 
Phosphatidylinositol 4-
phosphate 5-kinase-like protein 
1 
        45 
Isoform 4 of Cyclin-dependent 
kinase inhibitor 2A, isoform 3  
       37  




 15 716   34  
Janus kinase and microtubule-
interacting protein 1  
    13     
Ketosamine-3-kinase          51 
Mitogen-activated protein 
kinase kinase kinase 1 
  13    89   
Mitogen-activated protein 
kinase kinase kinase 15 
       39  
Mitogen-activated protein 
kinase kinase kinase 5  
       39  
Mitogen-activated protein 
kinase kinase kinase 6  
    27    42 
Mitogen-activated protein 
kinase kinase kinase kinase 4  
    39   39 29 
Myosin light chain kinase, 
smooth muscle  
       38 40 




adapter 1  
        38 
Nucleoside diphosphate kinase 
B  





  73       
Phosphoglycerate kinase 1   76       
Phosphoglycerate kinase 2         32  
Phosphoinositide 3-kinase 
regulatory subunit 5  
    16     
Protein kinase C alpha type      23   22  
Protein kinase C      28   22  
Protein-tyrosine kinase 2-beta     21     
Putative hexokinase HKDC1    174  54   20 19 
Pyruvate kinase PKM  30   767   19  
Rho-associated protein kinase      15   19 18 
Serine/threonine-protein kinase 
24  
    14     
Serine/threonine-protein kinase 
25 
       17  
Serine/threonine-protein kinase 
BRSK2  
       17  
Serine/threonine-protein kinase 
MRCK beta 
       17  
Serine/threonine-protein kinase 
SMG1  
14         
Serine-protein kinase ATM         16  
Serine-threonine kinase 
receptor-associated protein  
    42     
Tyrosine-protein kinase 
receptor 
      14   
 
In order to verify proteomics analysis result, we performed the Bio-peptide pull down assay. 
We noticed that the phosphorylation of peptide RSSRIK from MEKK1 was elevated in Bio-
7Aa but reduced in Bio-7A-associated samples, which was confirmed by Western blot 





Figure 3.8 The 7aa-peptide physically interacted with MEKK1.  
Bio-peptides/protein complex was trapped by streptavidin beads and subjected to Western 
blot analysis with anti-MEKK1 antibodies. 7S: scrabble 7aa-peptide; 7A: 7aa-peptide. 7Aa: 
7aa-peptide with serine substituted by alanine. B-7S/7A/7Aa: Biotin-labelled 7aa peptides. 
Data presented are representative images of three independent experiments. 
 
Then we performed time course assay and found that VEGF induced a transient increase of 
MEKK1 phosphorylation, peaked at 10min post-treatment (Figure 3.9A). The presence of 7A 
increased the de-phosphorylation of the phosphorylated MEKK1, while the addition of 7Aa 




Figure 3.9 VEGF transiently activated MEKK1 phosphorylation.  
(A) VPCs were treated with 5ng/ml VEGF in serum free medium for time duration indicated, 
followed by Western blot analysis with anti-phospho-MEKK1Ser393 (pMEKK1) and 
MEKK1 antibodies. GAPDH was included as loading control. (B) 7Aa retained MEKK1 
phosphorylation. VPCs were seeded in 96-well plates and pre-treated with 1ng/ml peptides in 
triplicate for 1hr, and then treated with 5ng/ml VEGF in the presence of peptides for time 
duration indicated, followed by ELISA with anti-phospho-pMEKK1(Ser393) antibody. 
Relative A405nm was defined as A405nm value with that of PBS/0hr group set as 1.0. 7Aa 
retained MEKK1 phosphorylation. The VPCs were treated with 5ng/ml VEGF in the 
presence of 1ng/ml peptides for 30min, followed by Western blot analysis with anti-
pMEKK1S393 and anti-MEKK1 antibodies. GAPDH was included as loading control.  Data 




To explore 7A effect on phosphorylated MEKK1, we also performed immunofluorescence 
staining on VPC cell.  The results show that the presence of 7A dramatically increased the 
de-phosphorylation of the phosphorylated MEKK1 (Figure 3.10). 
 
 
Figure 3.10 The presence of 7A attenuated VEGF-induced MEKK1 phosphorylation.  
VPCs were seeded on slides and pre-treated with 1ng/ml peptides for 1hr, and then treated 
with 15ng/ml VEGF in the presence of peptides for 30min, followed by immunofluorescence 
staining with anti-MEKK1 or anti-phospho-MEKK1Ser393 (pMEKK1) antibodies. The 
nucleus was counterstained with DAPI. Scale bar: 50μm.  Data presented are representative 
images of three independent experiments. 
 
These observations imply that MEKK1 may function as an upstream kinase for 7A 
phosphorylation. Indeed, knockdown of MEKK1 by siRNA significantly attenuated 7A 




Figure 3.11 Knockdown of MEKK1 attenuated VEGF-mediated 7A phosphorylation.  
The VPCs were transfected with MEKK1 siRNA (MEKK1si) and cultured for three days, 
followed by 5ng/ml VEGF treatment in serum free medium for 30 min. Control siRNA (ctlsi) 
and 1% BSA were included as siRNA and vehicle control respectively. The cell lysate was 
subjected to Bio-peptide/streptavidin-agarose beads pull-down arrays, followed by ELISA 
with anti-phospho-Ser antibody.  Data presented are mean of three independent experiments. 
*: p<0.05; **: p<0.01. 
 
So far, we have demonstrated that VEGF could induce HDAC7 undergo alternative 
transcription and translation to produce a 7-aa peptide, and this peptide could accept 
phosphate from MEKK1. The next question is whether 7A phosphorylation is the endpoint of 





3.2.3.2 The phosphorylated 7aa-peptide directly phosphorylated 14-3-3γ protein 
14-3-3 proteins are a family of conserved regulatory molecules ubiquitously expressed in all 
eukaryotic cells. Our previous study found that HDAC7 could regulate cell growth by 
directly binding to 14-3-3 protein (Margariti et al., 2010). From the pilot proteomics study, 
we noticed that the phosphorylation of a peptide (RATVVESSEK) from 14-3-3γ protein was 
increased in Bio-7Ap (the serine residue was synthetically phosphorylated) and VEGF-
treated Bio-7A associated samples (Table 3.2). 
Table 3.2                                      Biotin-peptide binding Phosph-14-3-3 








Phosph 14-3-3 protein gamma  
Phosph 14-3-3 protein theta 




The physical binding of the Bio-7A and Bio-7Ap to 14-3-3γ protein was confirmed by 
Western blot analysis (Figure 3.12A). To test whether 7A was directly involved in 14-3-3γ 
phosphorylation, the phosphorylated bio-7A peptide was purified by pull-down assay and 
incubated with commercially available recombinant 14-3-3γ protein, followed by ELISA 
detection of 7Ap and Western blot analysis of phosphorylated 14-3-3γ. The phosphorylation 
signal in bio-7A was increased by VEGF but significantly reduced by further incubation with 
recombinant 14-3-3γ (Figure 3.12B, left panel). Accordingly, the 14-3-3γ phosphorylation 
was increased (Figure 3.12B, right panel). Direct incubation of 7Ap with recombinant 14-3-
3γ protein in buffer system could increase 14-3-3γ phosphorylation (Figure 3.12C), 
suggesting that the phosphorylation group in the serine residue of 7Ap can be transferred to 






Figure 3.12 The 7aa-peptide acted as a kinase for 14-3-3γ. 
(A) The phosphorylated 7aa-peptide physically interacted with 14-3-3γ. Bio-peptides/protein 
complex was trapped by streptavidin beads and subjected to Western blot analysis with anti- 
14-3-3γ antibody. (B) The 7aa-peptide mediated the 14-3-3γ phosphorylation. The cell lysate-
incubated biotin-labelled peptides were trapped with streptavidin beads and washed with SDS 
solution to remove the associated proteins, followed by incubation with 0.1μg 14-3-3γ and 
elution with SDS solution. The elute was subjected to Western blot (right), while the beads 
were subjected to ELISA with anti-phospho-Serine antibody (left). (C) The 7Ap peptide 
could phosphorylate 14-3-3γ. 14-3-3γ was incubated with peptides, followed by Western blot 
analysis with anti-phospho-Serine (pSer) and anti-phospho-Threonine (pThr). 50μg VEGF-
treated VPC lysate was included as positive control (ctl). Data presented are representative 
images or mean of three independent experiments. 7Ap: 7A-peptide with serine 
phosphorylated. *: p<0.05. 
 
As shown in Figure 3.12B (right), all Bio-7S group still shows obviously band on pThr 
antibody. So we wonder there might be contaminated kinases in recombinant 14-3-3γ protein. 
To explore whether 7Ap could directly transfer the phosphorylation group to 14-3-3γ without 
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the facilitation of other proteins, we purified the 14-3-3γ protein band from SDS-PAGE gel 
and incubated with peptides in gel after being renatured. As shown in Figure 3.13, 7Ap did 
increase the phosphorylation of the 14-3-3γ protein, suggesting that 7Ap can act as a kinase 




Figure 3.13 The 7Ap peptide phosphorylated 14-3-3γ in gel 
The 14-3-3γ bands were cut from the SDS-PAGE gel, renatured and incubated with peptides. 
The gel sections were rearranged and transferred to a PVDF membrane followed by western 
blot analysis with anti-phospho-thr (pThr) and anti-14-3-3γ antibodies. Data presented are 
representative images of three independent experiments. 
 
These results indicated that 7A could enhance VEGF-induced 14-3-3γ phosphorylation at 
Thr145 residue. Interestingly, the exogenous 7Ap could increase 14-3-3γ phosphorylation in 
the absence of VEGF treatment (Figure 3.14A), suggesting that 7A phosphorylation may be 
involved in 14-3-3γ phosphorylation. Immunofluorescence staining revealed that the 
phosphorylated 14-3-3γ was mainly located in nucleus and upregulated by VEGF treatment, 







Figure 3.14  7A phosphorylation involved in 14-3-3γ phosphorylation. 
 
(A) The 7aa-peptide enhanced VEGF-mediated 14-3-3γ phosphorylation. (B) The 7Ap 
induced 14-3-3γ phosphorylation and nuclear translocation. The VPCs were pre-treated with 
1ng/ml 7S or 7Sp (the serine was synthetically phosphorylated) or 7A or 7Ap for 1hr and 
then treated with 5ng/ml VEGF in the presence of the peptides for 30min, followed by 
immunofluorescence staining with anti-phospho-14-3-3γThr145 (p14-3-3γ) and anti-14-3-3γ 
antibodies.  PBS was included as control for peptides or biotin-labelled peptides. BSA was 
used as vehicle control for VEGF treatment. Data presented are representative images or 




3.2.3.3 MEKK1-7A-14-3-3γ signal pathway. 
As we have verified that 7A got phosphate group from activated MEKK1 and that 7Ap could 
transfer the phosphate group to 14-3-3γ, we wondered whether 7A bridged between MEKK1 
and 14-3-3γ. Knockdown of MEKK1 by siRNA decreased the basal and abolished VEGF-
induced 14-3-3γThr145 phosphorylation (Figure 3.15A), indicating that MEKK1 is an 
upstream kinase for 14-3-3γ phosphorylation. In MEKK1 knockdown VPCs, the addition of 
7Ap alone could induce 14-3-3γThr145 phosphorylation (Figure 3.15B). 
 
Figure 3.15 MEKK1 is an upstream kinase for 14-3-3γ phosphorylation 
(A) Knockdown of MEKK1 abolished VEGF-induced 14-3-3γ phosphorylation in 
differentiated VPCs. (B) The 7Ap peptide induced 14-3-3γ independent of MEKK1. The 
MEKK1 knockdown VPCs were pre-treated with 0.1ng/ml peptides for 1hr and then treated 
with 10ng/ml VEGF for 30min, followed by Western blot with anti-p14-3-3γ (pThr). Data 
presented are representative images of three independent experiments. 
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3.2.3.4 The adjacent histidine and proline residues were essential for the 
phosphorylation transfer 
To investigate whether the two adjacent amino acid residues, histidine and proline, were 
involved in the phosphorylation transfer, we synthesized biotin-labelled mutant 7-aa peptides, 
in which the histidine residue was substituted as lysine (B-7Ak), arginine(B-7Ar), leucine (B-
7Al) and threonine (B-7At) respectively or proline was substituted as valine (B-7Av). The 
peptide pull-down assays were performed with these mutant peptides and VEGF-
treated/untreated VPC cell lysates. As shown in Figure 3.16, phosphorylated serine could be 
detected in B-7Ak and B-7Ar under VEGF treatment although it was significantly attenuated 
as compared to 7A. There was no phosphor-serine signal in other three mutants. These results 
suggest that an alkaline residue on the left side and a proline on the right side are essential for 
the phosphorylation of the serine residue in 7-aa peptide.  
 
Figure 3.16 An alkaline amino acid and proline was essential for the phosphorylation 
reception.  
An alkaline amino acid and proline flanking the serine residue was essential for the reception 
of phosphorylation from VEGF pathway. Biotin-labelled peptides were incubated with cell 
lysate from VEGF-treated/untreated VPCs (5ng/ml in serum free medium for 30min), 
followed by streptavidin-agarose beads pull-down and ELISA with anti-phospho-Ser 




To further assess whether these substitutions affect the phosphate group transfer to target 
protein, recombinant 14-3-3γ was incubated with synthetic phosphorylated mutant 7-aa 
peptides, followed by western blot analysis of 14-3-3γ phosphorylation. As shown in Figure 
3.17, all the substitutions lost the ability to transfer the phosphate group to 14-3-3γ, 
suggesting that histidine and proline are essential for this phosphorylation transfer. 
 
Figure 3.17 Histidine and proline are essential for this phosphorylation transfer. 
Both histidine and proline were critical to phosphorylate14-3-3γ.14-3-3γ (10ng) was 
incubated with phosphorylated peptides (1ng) in cell free buffer system, followed by Western 
blot with anti-phospho-14-3-3γThr145 (p14-3-3γ) and anti-14-3-3γ antibodies.  
 
Histidine is one of the four amino acids that can be phosphorylated in both bacterium and 
eucaryon (Klumpp & Krieglstein, 2005; Muimo et al., 2000). As described above, the 
histidine residue was not essential to receive phosphorylation at serine residue in 7-aa peptide 
but critical to transfer the phosphate group to 14-3-3γ, thus we wondered whether there was a 
phosphorylation transfer between the histidine and serine residues within 7-aa peptide. Indeed, 
phosphorylated histidine in N1 but not N3 position could be detected in 7Ap but not in 7Sp or 
7Av (Figure 3.18A). As expected, the phosphor-serine signal was significantly reduced in 





Figure 3.18 Phosphate group could be transferred from serine to histidine intra-
molecularly.  
The phosphorylated peptides (10μg) were coated onto microtiter plates, followed by ELISA 
with anti- phosphor-histidine (1-pHis and 3-pHis, A), phosphor-Ser (B) antibodies. 50μg 
VEGF-treated VPC cell lysate was included as positive control for phosphor-histidine. Data 




As histidine phosphorylation signal was low in B-7Ap and unable to be detected in peptide-
pull-down assays, we synthesized a C-terminal biotin-labelled 7Ap (B-c7Ap) which kept 
similar level of phosphor-serine and phosphor-histidine signals. With this peptide, we 
assessed whether there was any change on phosphor-histidine level during phosphorylation 
transfer from 7Ap to 14-3-3γ. As expected, the phosphor-serine signal was significantly 
reduced after incubation with 14-3-3γ (Figure 3.19A). However, there was only a slight 
decrease of phosphor-histidine signal (Figure 3.19B). 
 
Figure 3.19 Phosphor-serine was the source of phosphate for 14-3-3γ phosphorylation. 
14-3-3γ (10ng) was incubated with Biotin-labelled 7Sp (B-7Sp) or c7Ap (B-c7Ap) peptides 
(1ng) in cell free buffer system, followed by streptavidin-agarose beads pull-down. The beads 
were subjected to ELISA with anti-Phospho-Ser (A) and anti- Phospho-Histidine N1 (B) 





Serine is one of three amino acid residues that are commonly phosphorylated by kinases 
during cell signalling pathway in eukaryotes. Phosphorylated serine residues are often 
referred to as phosphoserine (Gehrig, Roschitzki, Rutishauser, Reiland, & Schlapbach, 2009). 
As 7A contains a serine, we wonder whether it occurs phosphorylation. As shown on Figure 
3.7A, more phosphoserine detected on Ad-HDAC7FH infected cell in the presence of VEGF. 
The phosphoserine might be from phosphorylation of phosphor-7A or 7A binding 
phosphoproteins. Then the 7aa-peptide phosphorylated assay was performed in cell free 
system, in which biotin marked 7aa-peptide was pulled down by streptavidin beads. 
Introduction of Biotin-Streptavidin system increase the stability of peptide-beads binding to 
prevent SDS elution, which can isolate peptide from binding proteins and make phosph-7A 
detection possible.  
Normally, a kinase has multiple phosphorylation sites, each site may correspond to a set of 
substrates. Therefore, a kinase can participate in different cellular processes via receiving 
phosphate group at different sites and transferring the phosphate group to different substrates.  
From the proteomic data, we found that p-MEKK1 specific binding with 7Aa, especially in 
the presence of VEGF, indicating that VEGF induced p-MEKK1 accumulated in 7Aa group 
which inhibit  phosphate group transfer for its similar structure with 7A. The presence of 7A 
accelerated the dephosphorylation of the VEGF-induced MEKK1 phosphorylation at Ser393 
site, suggesting that 7A may facilitate the phosphate group transferring from this site. Thus, 
we demonstrated that 7A is the substrate of MEKK1 to receive phosphate group from the 
serine393 residue. The MEKK1 knockdown significantly attenuated but not blocked VEGF-
induced 7A phosphorylation, suggesting that MEKK1 is one of the upstream kinases for 7A 
phosphorylation. However, these results did not show the directly evidence for 7A binding to 
pMEKK1 and receiving phosphate group from pMEKK1. The phosphate group transfer 
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assays from recombinant pMEKK1 protein to 7A in cell-free system will be performed in 
future work.  
7A is the substrate of MEKK1 to receive phosphate group, also transfers this phosphate 
group to downstream target proteins. Based on previous results and proteomic data, 14-3-3γ 
might be the target of 7A. In the presence of 7A, p14-3-3γ increased under VEGF treatment 
30 mins. Furthermore, the 7Ap can increase P14-3-3γ without VEGF, suggesting  that 7Ap 
might be the product of 7A with the treatment of VEGF. The binding of 7Ap to 14-3-3γ 
protein may cause huge conformation changes among both of them, creating enough energy 
to complete the phosphate group transferring from the serine residue in 7Ap to the threonine 
residue in 14-3-3γ. So we wonder whether the amino acid sequence in 7A is essential in the 
phosphorylation. Under the cell-free system, 7Ap directly phosphorylates 14-3-3γ protein. 
Although His/Lys or His/Arg substitution didn’t affect 7-aa peptide to receive 
phosphorylation at serine residue, the transferring of the phosphate group to 14-3-3γ 
definitely needed the involvement of the histidine and proline residues. Interestingly, the N1 
but not N3 site in histidine could receive the phosphate group from phosphor-serine during 
which the proline ring might facilitate. We may assume that upon binding to 14-3-3γ protein 
the phosphate group is transferred from histidine N1 site to the threonine residue in 14-3-3γ, 
while the empty N1 site receives phosphate from serine in which proline facilitates this 
intramolecular phosphorylation transfer. The significance of this striking finding is that a 
peptide or protein with HSP residues, such as 7A, transfers phosphorylation from a kinase to 
an effector independently of the direct interaction between the kinase and the effector, 
extending the spectrum of the effectors downstream of a kinase. 
For a protein kinase, normally contains regulatory domain and kinase domain, and kinase 
domain contains hydrophobic motif, turn motif and activation loop, which first identified in 
protein kinase C. Phosphorylation at the hydrophobic motif can regulate the catalytic function, 
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stability or phosphatase sensitivity which shows different function on different protein 
kinases (Keshwani, von Daake, Newton, Harris, & Taylor, 2011). The turn motif was 
regarded as a phosphorylation switch that regulates the kinase binding with other 
proteins(Knighton et al., 1991) (T. Gao & Newton, 2002). 7aa-peptide, a small peptide, does 
not contain the classically kinase domains, but can transfer phosphate group and function as a 
kinase. Firstly, 7aa-peptide is small so it might be easier to bind with proteins, for some 
proteins have the groove domain such as 14-3-3γ. Then the chemic structure of 7A contains 
two rings (Figure 3.20), and the rings may form the net structure which is easier to share the 
energy and transfer the phosphate group to the target proteins. Finally, for the small 
molecular, 7aa might to perform more high-efficiency. However, these are speculations the 
mechanism and chemical basis is still unknown and we will explore in the future work. 
 
Figure 3.20 Chemical structure of 7A 
 
3.2.5  Conclusions 
7aa peptide acts as a phosphate group carrier in MEKK1-7A-14-3-3γ signal pathway. The 
















Vascular endothelium injury is a common pathophysiological change in cardiovascular 
diseases. Traditional treatment aims to inhibit further injury through specific drug to protect 
vascular. However stimulating self-repairing to recovery the injury seems more beneficial 
and useful. 
Adventitial vasa vasorum constitutes a complete vascular tree-like structure, including 
arterioles, capillaries, and veins (Langheinrich et al., 2007). Under pathological conditions, 
the arterial adventitia undergoes remodelling in response to a variety of arterial injuries. The 
resident adventitial cells are often the first to be activated and reprogrammed in arterial wall 
remodelling (Stenmark et al., 2011). Recent studies suggest a more complex and dynamic 
picture of the adventitia which emphasizes critical roles played by interacting adventitial cell 
types in growth, inflammation, repair, and disease of the artery wall (Majesky et al., 2012). 
Accumulating evidence showed that the adventitia contains resident vascular stem 
cells/progenitor cells (Campagnolo et al., 2010; Hoshino et al., 2008; Passman et al., 2008). 
These Sca-1+ progenitor cells could be cloned in vitro, having the migration ability and 
multi-lineage potential to differentiate into osteoblasts, adipocytes, pericytes, ECs and SMCs 
under selective differentiation-promoting stimulation in culture. Furthermore, these 
progenitor cells appear to act in concert as part of a coordinated healing response to vascular 
injury. The progenitor cells may also contribute to vascular disease development.  
 
3.3.2 Hypothesis and Aims 
We hypothesis that 7A play an role on VPCs  though MEKK1-7A-14-3-3γ signal pathway 
and contribute to angiogenesis. 
In this chapter, we aim to verify  7A effect on proliferation, migration and differentiation of 




3.3.3.1 The 7aa-peptide induces VPC colonies formation and proliferation. 
As described above, the 7A peptide could be alternatively translated in VPCs in response to 
VEGF treatment and might be involved in signal transduction via acting as a phosphorylation 
carrier. The next question is what role it may play in the cellular behaviour. BrdU 
incorporation and MTT assays revealed that 7A had no effect on cell proliferation (Figure 
3.21A) on serum free medium or cell survival under oxidative stress (Figure 3.21B). 
 
Figure 3.21 7A had no significantly effect on VPC proliferation and survival 
(A) The 7aa-peptide slightly increased VPC proliferation. The 3-day differentiated VPCs 
were treated different concentration of 7S or 7A peptides in the presence of 10ng/ml VEGF 
in serum free α-MEM medium for 24hr. BrdU labelling reagents were added 6hr prior to 
harvesting the cells for BrdU incorporation assays. PBS and 1%BSA were used as control for 
peptide and VEGF respectively. The relative A405nm was defined as that of PBS/BSA group 
set as 1.0. (B) The 7aa-peptide had no effect on cell survival under oxidative stress. The 3-
day differentiated VPCs were treated 50μm and 100μm H2O2 for 24hr in the presence of 
1ng/ml 7S or 7A peptide, followed by MTT assays. The relative A490nm was defined as that 




As progenitor cell have the self- renew function, we wonder whether 7A has effect on VPC 
self–renew. Therefore, in a limited dilution assay was performed in 96-well plates with 
normal growth medium, the presence of 7A especially 7Ap significantly increased the colony 
numbers and cell numbers within a colony (Table 3.3). Besides, in clonogenic assay 
performed in 6-well plates, 7A especially 7Ap dramatically  increased the cells numbers per 
colony ( Table 3.4) and the average area occupied by per cell (Figure 3.22). These results 
suggest that 7A especially 7Ap increase VPC self-renewal and may also increase VPC 
migration. 
 





Table 3.3 Distribution of VPC Colonies (7days) 
VPCs were seeded in 96-well plates at density of one cell/100μl/well in the presence of 
1ng/ml peptides in stem cell medium for 7 days with medium refreshment every other day. 
PBS was included as vehicle control. Cells and colonies were observed under microscope 
after staining with Giemsa. The Table shows the distribution of colonies with different cell 
numbers, total colony number and average cell number per colony. Data presented were mean 
of three independent experiments. 
  
 





PBS 13 20 5 0 38 24 
7S 7 18 8 0 33 31.2 
7Sp 3 17 6 0 26 32.1 
7A 7 15 12 7 41 55.7 
7Ap 0 32 13 11 56 66.9 
7Aa 12 20 6 0 38 30.2 












Figure 3.22 7A increased VPC migration. 
VPCs were seeded in 6-well plates at density of 100 cells/well in the presence of 1ng/ml 
peptides in stem cell medium for 3 days. PBS was included as vehicle control. Cells and 
colonies were observed under microscope after staining with Giemsa. Table 5.2 shows the 
distribution of colonies with different cell numbers, total colony number and average cell 
number per colony Panel (A) shows cell distribution of typical colony in each group. Panel 
(B) shows the average area occupied by a single cell within a colony. Data presented were 
representative image or mean of three independent experiments. *: p<0.05. 
  
% 2～5 5～10 11～15 16～20 ＞20 
PBS 
24.18 35.34 23.25 14.42 2.79 
7S 
33.23 37.27 19.56 5.9 4.03 
7Sp 
32.14 38.09 23.81 2.38 3.57 
7A 
17.36 25.19 27.67 17.74 12.02 
7Ap 
10.22 20.12 29.41 21.52 18.73 
7Aa 
30.54 42.36 19.35 4.73 3.01 
Table 3.4               Distribution of Cell Numbers per Colony (3days) 
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3.3.3.2 The 7aa-peptide enhanced VEGF-induced VPC migration via MEKK1-7Ap-14-
3-3γ 
In order to identify the effect of 7A on VPC migration, The transwell migration assays were 
performed and the results showed that 7A increased and significantly enhanced VEGF-
induced VPC migration. 7Ap alone dramatically stimulated VPC migration, which was 
comparable to that observed in VEGF plus 7A (Figure 3.23). The stimulatory effect on VPC 
migration was also observed using the wound healing model (Figure 3.24). 
 
Figure 3.23 The 7aa-peptide enhanced VEGF-induced VPC migration 
The 7aa-peptide enhance VEGF-induced VPC migration. The 3-day differentiated VPCs 
were seeded in the insert and serum free medium containing 1ng/ml peptides with/without 
10ng/ml VEGF was added into the holder of transwell plates. Migrated cells were stained 
with crystal violet and observed under microscope 6hr later. (A) Panel shows the images of 
the migrated cell (B) panel shows the average cells/view. 1% BSA was included as control. 









Figure 3.24 7Ap significantly increased VPC migration in a wound healing model. 
Wound was introduced into confluent 3-day differentiated VPCs by tip scratching, and 
incubated with α-MEM medium containing 2% FBS and 1ng/ml 7S, 7A or 7Ap peptide. (A) 
Images were taken at 0, 12, 24 and 36hr post scratching. (D)The migrated cells in scratched 
area were counted from 3 views per scratching, 3 scratchings per well and 3 wells per peptide. 





As we have verified that MEKK1 is an upstream kinase for 14-3-3γ phosphorylation. We 
wonder whether MEKK1-7Ap-14-3-3γ signal pathway involved in 7A induced VPCs 
migration. In the transwell migration assays, knockdown of MEKK1 or 14-3-3γ decreased the 
basal level and abolished VEGF-induced VPC migration (Figure 3.25), suggesting that both 
MEKK1 and 14-3-3γ are essential for VPC migration. In MEKK1 or 14-3-3γ knockdown 
cells, 7A had no stimulatory effect any more, suggesting that MEKK1 and 14-3-3γ are also 
essential for 7A-mediated VPC migration. However, 7Ap alone could induce VPC migration 
in MEKK1 but not in 14-3-3γ knockdown cells, indicating that 7Ap is downstream of 
MEKK1 but upstream of 14-3-3γ. 
 
 




Knockdown of MEKK1 or 14-3-3γ abolished VEGF-induced VPC migration. Transwell 
migration assays were performed on control siRNA (ctlsi), MEKK1 siRNA (MEKK1si) and 
14-3-3γ siRNA (14-3-3γsi) transfected VPCs with 1ng/ml peptides and 10ng/ml VEGF. The 
upper panel shows the crystal violet staining images while the lower panel shows the mean 
value of migrated cells per view. Data presented are representative images or mean of three 
independent experiments. *: p<0.05. **: p<0.01. 
 
3.3.3.3 7aa-peptide enhanced VEGF-induced VPC differentiation toward EC lineage in 
vitro via MEKK1-7A-14-3-3γ signal pathway 
When ESCs differentiate into smooth muscle cells (SMCs), the HDAC7 transcript variant 2 
undergoes further splicing, leading to the incorporation of 7A into the far N-terminal end of 
HDAC7 protein (Margariti et al., 2009). Thus, we assumed that the 7A might be involved in 
cell differentiation process. VPCs were cultured in differentiation medium in the presence of 
7A and/or VEGF, followed by quantitative RT-PCR analysis of EC and SMC marker 
expression. As shown in Figure 3.26A, 7A increased CD31 and CD144 mRNA levels, which 
was significantly enhanced by VEGF although VEGF alone only had slight effect. The effect 
of 7Ap alone on CD31 and CD144 expression was comparable to the combined effect 7A and 
VEGF. 7A alone had no effect on SM22 expression but significantly decreased SM22 
expression in the presence of VEGF, although VEGF had slight increasing effect. 7Ap alone 
significantly decreased SM22 expression. These results suggest that 7A especially 7Ap 
favours VPC differentiation toward EC lineage while suppresses SMC differentiation. The 






Figure 3.26 The 7aa-peptide enhance VEGF-induced VPC differentiation toward EC 
lineage. 
The 7aa-peptide induced VPC differentiation toward EC lineage. The VPCs were cultured in 
differentiation medium in the presence of 0.1ng/ml peptides with/without 10ng/ml VEGF for 
7 days, followed by quantitative RT-PCR analysis of CD31, CD144 and SM22 mRNA levels 
(A) or Matrigel tube formation assess (B). Data presented are representative images or mean 
of three independent experiments. *: p<0.05. **: p<0.01.  
 
We have identified 7A is downstream of MEKK1 but upstream of 14-3-3γ, and MEKK1-
7Ap-14-3-3γ involved in 7A regulated VPC migration. Similar trend was observed on their 
effect on CD31 and CD144 expression in differentiated VPC cells (Figure 3.27). Interestingly, 
knockdown of MEKK1 especially 14-3-3γ increased SM22 expression. The inhibitory effect 
of 7Ap on SM22 expression was decreased by 14-3-3γ knockdown. These results suggest 






Figure 3.27 MEKK1-7A-14-3-3γ mediated 7aa-peptide induced VPC differentiation 
toward EC lineage. 
The VPCs were cultured in differentiation medium and transfected with siRNA in the 
presence of 0.1ng/ml peptides with/without 10ng/ml VEGF for 7 days, followed by 
quantitative RT-PCR analysis of CD31, CD144 and SM22 mRNA levels. Data presented 




3.3.3.4 The 7A increased vascular injury repair and angiogenesis in ischemic tissues in 
vivo. 
As 7A is able to enhance EC differentiation from VPCs in vitro, several animal models have 
been performed to check whether this peptide could also induce VPC differentiation in vivo. 
A wire-guided femoral artery injury model was then introduced in ApoE
-/-
 mice (Xiao et al., 
2006). Because 7A can enhance EC differentiation from VPCs in vitro, several animal 
models have been performed to assess whether this peptide could also induce VPC 
differentiation in vivo. Pluronic-127 gel containing 10ng/ml of peptides or PBS was applied 
surrounding the adventitia of the injured vessels, which were harvested 4 weeks post-surgery. 
The HE staining of cryo-sections revealed that 7A or 7Ap administration significantly 




Figure 3.28 The 7A and 7Ap peptides attenuated neointima formation. 
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The 7A and 7Ap peptides attenuated neointima formation in mouse femoral artery wire-
guided injury model. A panel shows the H.E. staining images of injured vessel sections 4 
weeks post-surgery. B panel shows the average intima plus media area from 6 mice with that 
of PBS group set as 1.0. Data presented were representative image or mean of three 
independent experiments. *: p<0.05. 
 
 
Besides, A hindlimb ischemia model was introduced in C57BL/6J mice, in which Pluronic-
127 gel containing 10ng/ml peptides was applied surrounding the injured vessels (L. Zeng, 
Xiao, et al., 2013). Foot blood perfusion was measured by a Doppler Scanner at day 7 and 
day 14 post-surgery. These experiments were performed in 8-month (Figure 3.29A) and 10-
weeek (Figure 3.29B) old mice. Although different age mice showed different recovery rate 






Figure 3.29 The 7A especially 7Ap peptide increased foot blood perfusion in mouse 
hindlimb ischemia model.  
The hindlimb ischemia model was introduced into 8-month (A) / 10-week (B) old C57bl/6 
mice by ligating and cutting the femoral artery in the right side. 200µl of F-127 pluronic gel 
containing 10ng/ml peptides was applied to the injured area. Foot blood flow was measured 
by Doppler Scanner at day 7 and day 14 post-surgery. Left panel shows the representative 
images of 6 mice for each group. The right panel shows the ratio of foot blood flow in the 
right injured side to that of the left uninjured side. *: p<0.05.  
 
Immunofluorescence staining on the skeletal muscle sections with anti-CD31 and anti-Sca1 
antibodies revealed more double positive cells in the 7Ap group (Figure 3.30). Importantly, 
many Sca1+ cell clusters were noted in the 7Ap group (Figure 3.30). These results suggest 
that 7A, especially 7Ap, stimulates VPC migration, proliferation and differentiation toward 
the EC lineage in vivo, contributing to vascular injury repair and angiogenesis in ischemic 
tissues.  
 
Figure 3.30 7A, especially 7Ap, stimulates VPC migration, proliferation and 
differentiation toward the EC lineage in vivo. 
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The peptide 7Ap increased Sca1+ (green) cell migration into the ischemic tissue and 
differentiation into CD31+ cells (red). (A) The left panel depicts representative 
immunofluorescence staining images on a skeletal muscle section from the injured leg. 
Arrow indicates the Sca1+ cell niche.  The right panel shows the mean±SEM CD31+ /Sca1 +   
cells from six 20x views of each of the six mice per group. Scale bar: 50 μm. (B) 7Ap 






14-3-3γ protein belongs to 14-3-3 family, a group of conserved regulatory molecules, that are 
expressed in all eukaryotic cells. 14-3-3 family was already found to participate in the 
formation of the adherens junctions through interaction with catenins and plakoglobin 
complex, therefore controlling the neighboring cell-to-cell connections, and the intercellular 
and extracellular matrix-to-cell communications (Klezovitch & Vasioukhin, 2015; Morrison, 
2009; Sehgal et al., 2014). In current study, 14-3-3γ protein is the effector of the MEKK1-
7A-14-3-3γ signal pathway, as knockdown of 14-3-3γ abolishes VEGF or 7Ap-induced VPC 
migration and differentiation toward EC lineage.  
Recently, in vitro experiments indicated that 14-3-3γ overexpression also played a potential 
role in cancer invasion (Raungrut et al., 2014), suggesting that 14-3-3γ protein plays an 
important role of in cell migration. In this study, knockdown of 14-3-3γ protein abolished 
VEGF or 7Ap-induced VPC migration, confirming the role of 14-3-3γ protein in VPC 
migration. VEGF or 7Ap increased 14-3-3γ protein phosphorylation at Thr145 site. 
Interestingly, increased phosphorylated 14-3-3γ was translocated to the nucleus, while the 14-
3-3γ in cytoplasm shows no significantly changes. On the one hand, the nuclear translocation 
of 14-3-3γ protein may break down the cadherin/catenin/plakoglobin/14-3-3complex 
formation. Therefore, the cells lose cell-to-cell connection, contributing to cell migration. On 
the other hand, the phosphorylated 14-3-3γ protein in the nucleus may be involved in the 
regulation of gene transcription that is responsible for cell migration and differentiation. 
However how 14-3-3γ regulating cell migration is still not clear, and need to explore in 
further work.  
In vivo, ischemic model were performed on 10 weeks and 8 months mouse. 7A and 7Ap 
shows much more effective on the 8 months mouse compared with 10 weeks mouse, though 
7AP increased blood recovery significantly on both. 10 weeks mouse might be more sensitive 
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to injury, which will result in much stronger self-recovery and cover the 7A effect. The 
staining results suggested 7Ap might induce VPC migration to form a nitch like structure. A 
single cell colony formation assay verified that 7Ap promote VPC self-renew, proliferation 
and migration. As 7Ap shows such a strong function in promote angiogenesis in mouse, we 
wonder whether it would be also functional in human, which may have the potential to be a 
new therapeutic way in vascular disease. The role of 7Ap in human ECs and ES will be 
verified in our future work, and which may provide the basis of 7Ap to be a potential new 
drug. 
Progenitor cell differentiation is such a complicated process that multiple signalling pathways 
are involved in. 7Ap promoted VPCs differentiation towards functional EC. Knockout 14-3-
3γ abolished 7Ap-induced EC differentiation, indicating MEKK1-7A-14-3-3γ pathway is 
involved in EC differentiation. Besides, proteomic data also showed that 7A may participate 
in cell cycle regulation, as binding with CDK and other related proteins. Whether 7A 
regulates cell differentiation via cell cycle regulation would be an interesting project, and we 
will give a brief describe in the future work part. 
 
3.3.5 Conclusions 
The 7aa-peptide induces VPC proliferation, VEGF-induced migration and differentiation 
toward EC lineage in vitro via MEKK1-7A-14-3-3γ signal pathway. Furthermore, the 7A 














4.1 Including Discussion 
It is widely accepted that one mRNA molecule produces one peptide/protein. However, more 
and more evidence suggests that one mRNA molecule may produce several peptides through 
different ORFs or non-ATG-translation (Chu, Ma, & Saghatelian, 2015; Cleary & Ranum, 
2014). In this study, we demonstrate that a sORF within the 5’-UTR of mouse HDAC7 
transcript variant 2 can be translated to produce a biologically active 7aa-peptide, 
contributing to the Sca1
+
 progenitor cell self-renewal, migration and differentiation toward 
EC lineage. The most important finding from this study is that this 7aa-peptide can 
participate in the signal transduction via acting as phosphorylation carrier, shedding new 
lights on the biological functions of the HDAC7 gene. 
4.1.1 HDAC7 transcript variant 2 undergoes alternative transcription and translation 
There are eight transcript variants in mouse HDAC7 mRNA molecules, producing different 
HDAC7 proteins with two types of the N-terminals. The transcript variants 3 and 4 have 22 
amino acids more in the N-terminal as compared to other variants. In the 5’UTR of HDAC7 
transcript variant 2, there is a sORF encoding 7aa-peptide with three cascade in-frame stop 
codons. The further splicing of this mRNA will join the sORF with the main ORF, producing 
the same N-terminal as transcript variants 3 and 4 (Margariti et al., 2009). The information 
indicates that the start codon of the sORF can really initiate the translation.  
However, it is unknown whether this sORF can be translated alone. In this study, with the 
artificial construct pShuttle2-HD7FH, we demonstrate that this sORF is indeed translated in 
VPCs. The co-existence of FLAG and HA at a comparable level within single VPC suggests 
that both ORFs can be translated simultaneously. There is no overlap on FLAG and HA  
immunofluorescence staining, reflecting that there is no interaction between the 7aa-peptide 
and HADC7 protein and that there is no further splicing to join the two ORFs. Indeed, we 
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didn’t detect HDAC7 in Bio-7A peptide pull down/proteomics studies. Our previous study 
showed that there was no splicing occurred in ESCs (Margariti et al., 2009). The exclusive 
staining of FLAG in the cytoplasm indicates that the 7A only locates in the cytoplasm. This 
should be true as it doesn’t contain nuclear location signals.  
 
4.1.2 7aa-peptide is essential for VPCs to maintain the pluripotency 
The translation of the 7aa-peptide from the sORF may be very important for the VPCs to 
maintain the pluripotency. The first supporting evidence to this notion was that 7A especially 
7Ap significantly increased VPC colony formation and cell numbers within a single colony. 
Further direct evidence came from the observation that 7Ap significantly increased Sca1
+
 cell 
niche numbers in a mouse model. The indirect evidence was the observation that the ratio of 
FLAG to HA was significantly reduced upon the spontaneous differentiation with the 
removal of leukemia inhibitor factor.  Further detailed investigation will be required to study 
whether leukemia inhibitory factor is involved in the translational regulation of the sORF and 
the underlying mechanisms.  
In addition to VPC self-renewal, 7A also seems to be involved in VEGF-induced VPC 
migration and differentiation toward EC lineage. VEGF could increase sORF translation as 
revealed by the increase in the ratio of FLAG to HA in differentiated VPCs under VEGF 
treatment. Exogenous 7A could enhance VEGF function on the aspects of migration and 
differentiation toward EC lineage. Of course, detailed investigation will be required to study 
how VEGF drives the translation of the sORF. 
 
4.1.3 7aa-peptide can function a kinase to transfer phosphate group  
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Besides demonstrating the translation of the sORF, the most important and striking finding of 
this study is that a 7aa-peptide can transfer phosphate group like a kinase. Protein 
phosphorylation is one type of post-translational modifications, which plays an important role 
in the cellular signal transduction. A phosphate group is originally transferred from a donor 
like ATP to a protein kinase, which in turn transfers the phosphate group to its substrate via 
protein-protein interaction. During this process, the kinase experiences phosphorylation-to-
dephosphorylation shift. Phosphorylation usually occurs on serine, threonine, tyrosine and 
histidine residues in eukaryotic proteins (Burnett & Kennedy, 1954; C. Chang & Stewart, 
1998; Cozzone, 1988; Stock et al., 1989). Normally, a kinase has multiple phosphorylation 
sites, each site may correspond to a set of substrates. Therefore, a kinase can participate in 
different cellular processes via receiving phosphate group at different sites and transferring 
the phosphate group to different substrates.   
In this study, we demonstrate that 7A is the substrate of MEKK1 to receive phosphate group 
from the serine393 residue. The MEKK1 knockdown significantly attenuated but not blocked 
VEGF-induced 7A phosphorylation, suggesting that MEKK1 is one of the upstream kinases 
for 7A phosphorylation. The presence of 7A accelerated the dephosphorylation of the VEGF-
induced MEKK1 phosphorylation at Ser393 site, suggesting that 7A may facilitate the 
phosphate group transferring from this site. The retaining of MEKK1Ser393 phosphorylation 
by the presence of 7Aa confirms that 7A acts as the phosphate group recipient. The 
serine/alanine substitution makes 7Aa lacking the ability to receive phosphate group.  To 
receive the phosphate group, an alkaline aa at the histidine residue seems essential as lysine 
or arginine substitution only slight reduced but leucine or threonine substitution totally 
abolished VEGF-induced 7aa phosphorylation. The proline ring seems critical for this 
phosphorylation process as substitution with valine (the same carbons) ablated 7-aa 
phosphorylation. Strikingly, 7A can directly transfer this phosphate group to the Thr145 
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residue of 14-3-3γ protein in a way like a kinase. The 7Ap not only increased 14-3-3γ protein 
phosphorylation at Thr145 site in living cells but also in a cell-free in-gel reaction system. 
Under the cell free system, 7Ap directly phosphorylates 14-3-3γ protein. The binding of 7Ap 
to 14-3-3γ protein may cause huge conformation changes among both of them, creating 
enough energy to complete the phosphate group transferring from the serine residue in 7Ap to 
the threonine residue in 14-3-3γ.  
The significance of this striking finding is that a small peptide such as 7A transfers 
phosphorylation from a kinase to an effector independent of the direct interaction between the 
kinase and the effector, extending the spectrum of the effectors downstream a kinase.  
 
4.1.4 MEKK1-7A-14-3-3γ signal pathway is involved in 7Ap-induced VPC migration 
and differentiation 
14-3-3γ protein is the effector of the MEKK1-7A-14-3-3γ signal pathway, as knockdown of 
14-3-3γ abolishes VEGF or 7Ap-induced VPC migration and differentiation toward EC 
lineage. 14-3-3γ protein belongs to a family of conserved regulatory molecules, participating 
in the formation of the adherens junctions through interaction with catenins and plakoglobin 
complex, therefore controlling the neighboring cell-to-cell connections, and the intercellular 
and extracellular matrix-to-cell communications (Klezovitch & Vasioukhin, 2015; Morrison, 
2009; Sehgal et al., 2014). An intact adherens junction keeps the cells quiescence via 
suppressing cell migration and proliferation. It has been reported that high level of 14-3-3γ 
protein was related to cancer cell invasion while ablation of 14-3-3γ protein led to neural 
migration delay (Raungrut et al., 2014; Wachi et al., 2015), suggesting that 14-3-3γ protein 
plays an important role of in cell migration. 
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In this study, knockdown of 14-3-3γ protein abolished VEGF or 7Ap-induced VPC migration, 
confirming the role of 14-3-3γ protein in VPC migration.  VEGF or 7Ap increased 14-3-3γ 
protein phosphorylation at Thr145 site, which was translocated to the nucleus. The nuclear 
translocation of 14-3-3γ protein may break down the cadherin/catenin/plakoglobin/14-3-3γ 
complex formation. Therefore, the cells lose cell-to-cell connection, facilitating cell 
migration. Moreover, the phosphorylated 14-3-3γ protein in the nucleus may be involved in 
the regulation of gene transcription that is responsible for cell migration and differentiation. 
 
4.1.5 The translation shift between 7aa-peptide and HDAC7 protein 
HDAC7 plays an important role in the maintenance of the cadherin-catenin complex (Hui, 
Brunt, & Husain, 2010; Margariti et al., 2010). It has been documented that PKD-mediated 
phosphorylation contributes to HDAC7 degradation leading to cell migration and 
proliferation (Sinnett-Smith et al., 2014; Wang et al., 2008). A recent report showed that 
VEGF-PKD1-HDAC7 pathway contributed to endothelial progenitor cell migration and 
differentiation toward EC lineage (Yu et al., 2014).  
In this study, we demonstrated that a short ORF encoding a 7aa-peptide could be translated 
from the 5’-UTR together with the main ORF as revealed by the occurrence of both FLAG- 
and HA-tagged peptides within a single cell. Importantly, there existed a translation shift 
from the main ORF to the short one within VPCs in response to VEGF treatment as revealed 
by the increase of FLAG to HA ratio. This translation shift will decrease HDAC7 protein, 
providing an alternative strategy to control HDAC7 protein level. The decrease of HDAC7 
protein may affect the cadherin-catenin complex, contributing to cell migration and 
proliferation. Taken together, we can assume that the changes on the cadherin-catenin 
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complex can be derived from the combined effect of the occurrence of the 7A and the 
decrease of HDAC7 protein.   
In summary, VEGF induces HDAC7 mRNA to undergo translation shift from the main ORF 
to the short one in VPCs, giving rise to a 7aa-peptide (7A). On the other hand, VEGF 
activates MEKK1 via phosphorylation at the Ser393 residue. The activated MEKK1 transfers 
the phosphate group from Ser393 to the serine residue within the 7aa-peptide. The 
phosphorylated 7aa-peptide (7Ap) in turn transfers the phosphate group to the Thr145 residue 
within 14-3-3γ protein, leading to cadherin-plakoglobin-catenin-14-3-3γ complex disruption 
and 14-3-3γ nuclear translocation. Other signal pathways may be also activated by 7Ap. The 
overall effect is to induce VPC proliferation, migration and differentiation toward EC lineage, 
leading to angiogenesis and vascular injury repair in vivo (Figure 4.1). The significance of 




Figure 4.1: A schematic illustration of VEGF-induced HDAC7 alternative translation 
and its role in VPC proliferation, migration and differentiation.  
VEGF binds to its receptor VEGFR-2, triggering the translational shift of HDAC7 from the 
main ORF to the sORF, giving rise to a 7aa-peptide (7A). VEGFR-2 activates MEKK1 
phosphorylation at Ser393 site. The phosphorylated MEKK1 transfers the phosphate group 
from Ser393 to the serine residue of 7A, forming the 7Ap. 7Ap transfers the phosphate group 
to Thr145 site within 14-3-3γ, leading to 14-3-3γ nuclear translocation, therefore disrupting 
the cadherin/plakoglobin (PLAK)/catenins (ctnns)/14-3-3γ complex. 7Ap may also activate 
other pathways. On the other hand, the decrease of HDAC7 protein may also contribute to the 
disruption of the cadherin/plakoglobin (PLAK)/catenins (ctnns)/14-3-3γ complex. The 
overall effect is to increase VPC proliferation, migration and differentiation toward EC 




4.2 Future Work 
4.2.1 Translational regulation of sORF and mORF of HDAC7-tv2 
Much effort has been made in this project to elucidate the 7A acts as a phosphate group 
carrier to transfer phosphate group from MEKK1 to 14-3-3γ. The production of 7A and the 
translational regulation of sORF of HDAC7 is still unknown. We wonder that protein or non-
coding RNA might bind to the upstream sequence of sORF or mORF to block or facilitate the 
access of ribosome.  
Firstly, we will compare the alternative translation among different cell types and conditions. 
In details, Ad-HD7FH  infection  will performed on  ES, differentiated ES, dES plus LIF or 
VEGF, VPCs, differentiated VPCs, dVPCs plus LIF or VEGF, mECs, mSMCs. ELISA with 
anti-FLAG and anti-HA antibodies will be performed to detect the translation of sORF and 
mORF5. These experiments will give us information whether there is alternative translation 
during these cellular processes and the potential role of the 7A peptide. 
Then, we will construct mHD7NC reporter system, in which the 5’UTR of mouse HDAC7  
mRNA was inserted in pSI-Check2 vector with the Renilla luciferase ORF fused  
with HDAC7 mORF. The expression level of Renilla luciferase will represent  
HDAC7 mORF expression. Transfection of this construct into ES, differentiated  
ES, dES plus LIF or VEGF, VPCs, differentiated VPCs, dVPCs plus LIF or VEGF,  
mECs, mSMCs, followed by Renilla/Firefly luciferase activity assay. These  
experiments will confirm data obtained from ELISA and provide a useful and          
convenient reporter system. 
Moreover, DNA fragments complementary to the upstream sequence of sORF and mORF 
will be synthesized respectively and transfected together with the HDAC7NC reporter into 
those cells to confirm data obtained from above. In order to identify the potential regulatory 
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proteins, Biotin-labelled RNA fragments will be synthesized identical to the upstream 
sequence of sORF and mORF respectively. RNA/Protein pull-down assay with cell lysate 
will be performed and isolated from cells described above, followed by proteomics analysis.  
These experiments will identify the potential regulatory proteins for the alternative translation.  
Finally, we will analyse the changes of the regulator proteins in different cells or different 
conditions. RT-PCR analysis will be performed to detect mRNA level of these proteins; 
Western blot will be performed to analyse the protein level changes and modification changes 
under different conditions; Double immunofluorescence staining or immunoprecipitation 
assay will be performed to detect the association of this candidate with translation initiation 
factors; A modified ChIP assay plus RT-PCR will be performed to amplify HDAC7 mRNA 
and ribosomal RNA; Mutant candidate protein, in which the modification site was substituted 
with  amino acid that is unable to undergo the modification, will be created to compare the 
mutant and wild type gene on HDAC7NC reporter. These experiments will give us 
information whether this protein bridges HDAC7 mRNA and ribosome. They will also give 
us the information on the role of the modification in the regulation of alternative translation. 
 
4.2.2 Explore the mechanism of the phosphorylated 14-3-3γ drive VPC migration and 
differentiation. 
There is no much work on 14-3-3γ, till now only 111 papers have been recorded in total. 
These are mainly in neuroscience and cancer research. In this study, my data revealed that 
this protein could be phosphorylated by 7Ap at Thr145 site, which drove the protein nuclear 
translocation. Knockdown of this protein abolished 7Ap-induced VPC migration and 
differentiation toward EC lineage. There are two main questions to be answered.   
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One question is that: Is the phosphorylation of Thr145 site essential for 14-3-3γ nuclear 
translocation and how is this regulated? We will create the Ad-FLAG1433G and Ad-
FLAG1433GT145V viral constructs. A FLAG tag will be fused to the N-terminal of 14-3-3γ 
protein. In the Ad-FLAG1433Gm construct, the Thr145 is substituted with valine, losing the 
ability to be phosphorylated. Immunofluorescence staining or cellular fractionation of virus 
infected VPCs that are treated with 7Ap will confirm the essentiality of Thr145 
phosphorylation in 14-3-3γ nuclear translocation. Next,  we will association of 14-3-3γ with 
kinesin. Kinesin is a motor molecule, trafficking proteins from cytoplasm into nucleus. The 
co-immunoprecipitation or double immunofluorescence staining assays will give us 
information whether there is affinity difference between the wild type and mutant 14-3-3γ to 
kinesin. These experiments will provide a mechanism on 14-3-3γ nuclear translocation. 
The other one is that: How does the phosphorylated 14-3-3γ drive VPC migration and 
differentiation? First and forest, the two viruses-infected VPCs were treated with 7Ap, 
followed by migration and differentiation assay respectively. These experiments will give 
direct evidence on the role of Thr145 phosphorylation in VPC migration and differentiation 
regulation. It is established that Akt is involved in cell migration. Our previous study has 
shown that Akt can form a complex with mTOR (Martin D, JBC 2014). It has been  
 reported that 14-3-3γ can up-regulate mTOR signalling. So, we will assess whether 14-3-3γ 
associates with mTOR and Akt and whether Thr145 phosphorylation facilitate this interaction. 
Co-immunoprecipitation and double staining will be performed using anti-FLAG and anti-
mTOR or Akt. We will also detect mTOR and Akt phosphorylation in control siRNA and 14-
3-3γ siRNA knockdown VPCs or viruses-infected VPCs following 7Ap treatment. 
Furthermore, immunoprecipitation will be performed with anti-FLAG antibody from cell 
lysates isolated from the two viruses-infected VPCs following 7Ap treatment. The 14-3-3γ 
associated proteins will be subjected to proteomics analysis. The proteins missing  
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 in the mutant 14-3-3γ may be the potential candidates responsible for migration  
 and differentiation. We will also pay attention to the phosphorylation changes of  
  the associated proteins. Some of the modification changed proteins are the  
  potential candidates, and the identification of potential candidates need to be verified using  
knockdown or pathway analysis. As phosphorylated 14-3-3γ is located in the nucleus, it is 
possible that this protein functions as a co-factor for gene transcriptional regulation. We can 
perform ChIP assay with anti-phospho-14-3-3γThr145 antibody. The isolated DNA fragment 
can be subjected to microarrays or DNA sequencing. The VPCs are paired as  
treated/untreated with 7Ap. These experiment might to draft the way of phosphorylated 14-3-
3γ drive VPC migration and differentiation. 
 
4.2.3 Explore the mechanism of 7Ap regulate VPC proliferation. 
Firstly, we will verify whether 7A translation is essential for VPC proliferation. Synthesize a 
DNA fragment complementary to the upstream sequence of the sORF and perform 
transfection into VPCs. These cells will be infected with Ad-mHD7FH, followed by ELISA 
with anti- FLAG and anti-HA antibodies. These experiments will assess whether the DNA 
fragment can block the translation of 7A. VPCs will be transfected with the DNA fragment 
followed by proliferation assay. These experiments will give us information on whether 7A is 
essential for cell proliferation.  Use CRISP/Cas technique to create an ES or VPC cell line 
that the sORF is deleted. Exogenous 7A or 7Ap can be added during the creation process. 
When the cell line was established, its self-renewal will be assessed in the absence or 
presence of exogenous 7A or 7Ap. If 7A is essential, there may be no colony formation in the 
absence of exogenous 7A.  
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Secondly, we will explore the effect of 7Ap on VPC cell growth and cell cycle progression. 
VPCs are treated with PBS, 7S, 7A or 7Ap for 7 days, followed by calculation of cell size 
and cell number every day to get information whether 7Ap has effect on cell growth in size 
and doubling time. VPCs are treated with PBS, 7S, 7A or 7Ap for 24hr, followed by  FACS 
analysis of cell cycle to get information whether 7Ap affect each cell cycle phase. 
Finally, we will identify how 7Ap drives VPC proliferation. From our pilot proteomics data, 
we found that 7A/7Ap was associated with some cyclin-dependent kinases. These CdKs may 
be good candidates on this aspect. We will go through the database again to check whether 
there are other proteins that are involved in cell cycle control. Then we will perform Western 
blot, cellular fractionation, immunofluorescence staining to check candidate modification and 
cellular location changes and perform microarrays on VPCs+7Sp vs VPCs+7Ap, VPCs vs 
mutant VPCs and VPCs+ZK770 vs VPCs+ZK771. Comparison among these three databases 
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7A, 7aa-peptide 7 amino acids peptide 
7Ap Phosph-7A 
7Sp Phosph-7S 
AP-1 activator protein 1 
ASK1 Apoptosis signal-regulating kinase 1  
bFGF  basic Fibroblast Growth Factor  
BBP branch-point binding protein  
Bcl-2  B-cell lymphoma 2 
Bio-7A Biotin marked 7A 
Bio-7Ap Biotin marked 7Ap 
Bio-7S Biotin marked 7S 
Bio-7Sp Biotin marked 7Sp 
CD3 cluster of differentiation 3 
CD31 cluster of differentiation 31  
CD34 cluster of differentiation 34 
CD44 cluster of differentiation 44 
CD45 cluster of differentiation 45 
CD73 cluster of differentiation 73 
CD90 cluster of differentiation 90 
CD105 cluster of differentiation 105 
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CD133 cluster of differentiation 133 
CD144 cluster of differentiation 144 
cDNA  complementary DNA  
CM  conditioned medium  
ctrl  control  
DAPI  4',6-diamidino-2-phenylindole  
ddH2O  Double distilled water  
DMEM  Dulbecco’s Modified Eagle's Medium  
DMSO  Dimethyl Sulfoxide  
dNTPs  deoxyriobonucleotide triphosphates  
ECs  Endothelial Cells  
ECM Extracellular matrix  
EDTA  Ethylenediaminetetraacetic Acid  
EGF Epidermal Growth Factor 
ELISA Enzyme-linked immuno sorbent assay 
ELISA  Enzyme-Linked Immunosorbent Assay  
eNOS Endothelial Nitric Oxide Synthase 
ERK Extracellular signal–Regulated Kinase 
ERK1/2  Extracellular signal–Regulated Kinase 1/2  
ESCs  Embryonic Stem Cells  
FBS  Fetal bovine serum  
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FGF Fibroblast Growth Factor  
GFP  green fluorescent protein  
HDAC Histone acetyltransferase 
HDACi Histone acetyltransferase inhibitors  
HE stian  Haematoxylin and Eosin stain  
HRP  Horseradish Peroxidase  
ICAM-1 Intercellular Adhesion Molecule 1 
IGF-1 Insulinlike growth factor 
IL  Interleukins  
JNK  c-Jun N-terminal kinase  
JNK1 c-Jun N-terminal kinase1  
kSDS  Sodium Dodecyl Sulfate  
LIF  Leukemia Inhibitory Factor  
MAPK Mitogen-activated protein kinase 
MEKK1 Mitogen-activated protein kinase kinase kinase 1 
MMP matrix metalloproteinase 
MMPs  Matrix Metalloproteinases  
mRNA Messenger RNA 
mRNA  messenger RNA  
MTT Methyl thiazolyl tetrazolium 
NO Nitric Oxide 
166 
 
NO  Nitric Oxide  
P1 Promoter1 
P2 Promoter2 
PDGF  Platelet-Derived Growth Factor  
PDGF-B platelet-derived growth factor B  
PDGF-BB  platelet-derived growth factor BB  
PDGFR-β  Beta-type platelet-derived growth factor receptor 
PKB protein kinaseB 
PKD protein kinase D 
PlGF Placental Growth Factor 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PP1 protein phosphatases 1 
PP1A protein phosphatases 2A  
pre-mRNA pre-messenger RNA  
qPCR Quantitative polymerase chain reaction 
qPCR  quantitative real time Polymerase Chain Reaction  
RTKs Tyrosine kinases  
RT-PCR  Reverse transcription polymerase chain reaction  
Sca-1  Stem cells antigen-1  
SEM  Standard Error of the Mean  
SiRNA small interfering RNA 
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siRNA  small interfering RNA  
SMCs  Smooth Muscle Cells  
snRNPs small nuclear ribonucleoproteins  
sORF Short open reading frame 
SSH1L slingshot 1-like  
TGF-β  Transforming Growth Factor beta  
TNF-α  Tumor Necrosis Factor alpha  
VCAM-1  Vascular Cell Adhesion Molecule-1  
VE-cadherin, CD144 Vascular endothelial cadherin 
VEGF Vascular endothelial growth factor 
VEGF  Vascular Endothelial Growth Factor  
VEGFR  Vascular Endothelial Growth Factor Receptor  
VEGFRs Vascular endothelial growth factor recepters 
VPCs Vascular Progenitor Cells  
WB Western Blot  
μg microgram 
μg  microgram  
μl microliter 
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